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Abstract
Despite the efficacy of contingency management (CM) in promoting smoking reduction
and abstinence, major barriers continue to hinder its widespread dissemination and
adoption. The present study addressed two of these barriers, inefficient response
requirements and high behavioral costs, by evaluating a novel payment schedule
implemented within a workplace setting. Nine university staff were enrolled in a 6-week
ABAB study design. During baseline weeks, participants earned money contingent on
session attendance. During CM weeks, participants earned money contingent on smoking
reduction or abstention payment arrangements, which were available concurrently.
Abstention payments increased in magnitude across treatment weeks whereas reduction
payments decreased. The results indicate that participants’ biological and self-report
measures of smoking did not systematically decrease during CM relative to baseline.
Additionally, 3 of the 9 participants did not complete the study. These findings suggest
that the current arrangement did not improve barriers related to response requirements
and behavioral costs. Significant methodological and practical limitations are discussed
as well as their implications for future research and on global concerns of CM for
smoking interventions.
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CHAPTER 1
Over the last century, the rates and causes of mortality in the United States have
changed drastically (Danaei et al., 2009; United States National Office of Vital Statistics,
1976). Unprecedented medical progress and advancements have allowed for the
successful treatment of acute illnesses and communicable diseases that once plagued
Americans, such as influenza and tuberculosis. Over the last 100 years, medical
developments undoubtedly have improved life quality and longevity; however, focus has
shifted to the treatment and prevention of chronic, rather than acute, diseases (New Jersey
Department of Health and Human Services, 2003). Chronic diseases, such as heart
disease and cancer, now account for the majority of deaths in the United States (Heron et
al., 2009), and unlike acute illnesses or communicable diseases, chronic diseases are in
large part the result of long-term patterns of unhealthy behaviors (Danaei et al.). One
such pattern that continues to be a challenge, in treatment and prevention, is smoking.
Smoking in the United States
According to a recent report from the Center for Disease Control and Prevention
(CDC, 2009), approximately 20.6% of adults in the United States self report being
current smokers. Although the percentage of the population reporting smoking has
decreased steadily from 37.4% in 1970 and from 24.1% in 1998, smoking rates did not
change dramatically from 2007 (19.8%) to 2008 (20.6%), suggesting that current efforts
to prevent smoking and promote abstinence may be inadequate. In the United States,
cigarette smoking is the leading preventable cause of mortality and morbidity, accounting
for an estimated 394,000 deaths each year, or one of every five deaths (CDC). These
estimated mortality rates due to smoking are higher than those caused by HIV, illegal
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drug use, alcohol use, motor vehicle injuries, suicides, and murders are combined
(McGinnis & Fogue, 1993). In addition to the direct impact on smokers, roughly 50,000
additional annual deaths are attributed to exposure to second-hand smoke among
nonsmokers (CDC, 2008).
Despite the numerous jobs and considerable income that tobacco production and
sales produce, smoking may weaken the strength of the United States’ economy. Each
year, an estimated $193 billion dollars are spent unnecessarily due to smoking-related
conditions (CDC, 2008). The sources of this deficit are due primarily to direct medical
costs and lost productivity, resulting in $96 and $97 billion dollar losses, respectively.
Additional economic costs not included in these statistics relate to the finances of
smoking itself. The average pack-a-day smoker spends over $1500 annually, money that
could be spent on healthier activities and an amount that places a significant burden on
smokers, especially among at-risk populations such as those of low socioeconomic status
(Julien, Advokat, & Comaty, 2008).
Smoking has negative health effects on virtually every organ in the body, and
therefore increases risks for a large range of diseases, including various cancers and
forms of cardiovascular disease (CDC, 2004). The impact of these health implications is
evident in the average life spans of nonsmokers and smokers, with the latter averaging
roughly 14 fewer years as a result of premature death due to smoking (CDC, 2002).
Fortunately, individuals who quit smoking can reverse some harmful effects of smoking,
greatly reduce their risk of premature death, and experience the immediate (e.g., lower
heart rate) and long-term (e.g., lower risk of cancer) benefits associated with smoking
cessation (CDC, 1990). Furthermore, cessation may reverse minor problems associated
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with smoking such as foul breath, premature wrinkling, and stained nails, which may
positively impact an individual’s social relationships.
Nicotine Dependence
Each year in the United States, approximately 900,000 new individuals become
dependent on nicotine, the psychoactive drug found in tobacco that causes addiction
(Julien et al., 2008). Similar to alcohol or cocaine, nicotine exerts numerous and potent
anxiolytic and stimulatory pharmacological effects on central and peripheral nervous
systems and various organs. Physiological effects of nicotine include decreased activity
in afferent nerve fibers, release of antidiuretic hormone, and increased heart rate and
blood pressure. Nicotine’s psychological or subjective effects include relaxation,
increased cognitive functioning and attention, and memory consolidation. Interestingly,
nicotine may reduce depressive symptoms, which may explain the high rates of
comorbidity of nicotine dependence and major depressive disorder (Salin-Pascual, Rosas,
Jimenez-Genchi, Rivera-Meza, & Delgado-Parra, 1996). In the central and peripheral
nervous systems, nicotine activates specific cholinergic receptors, facilitating the release
of dopamine, which is postulated to modulate the reinforcing actions of nicotine (Julien et
al.), whereas nicotine’s indirect effects on acetylcholine and glutamate may account for
the drug’s effects on memory and information processing.
Nicotine dependence, like dependence for other drugs of abuse (e.g., heroin), is
considered a clinical substance-related disorder in the DSM-IV-TR and is characterized
by (a) drug tolerance, (b) drug withdrawal symptoms, (c) increased use over time, (d)
excessive time spent seeking or using a drug, (e) drug use that interferes with daily
activities, and (f) persistent drug use despite knowledge of the drug’s negative
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physiological or psychological effects (American Psychiatric Association [APA], 1994).
Tolerance to nicotine is acute, can occur within a single episode of repeated
administrations (Perkins et al., 1994), and once developed requires continued use to avoid
a large class of physiological and psychological withdrawal symptoms. Symptoms
experienced during nicotine abstinence vary across individuals but typically include some
combination of insomnia, decreased concentration, impatience, irritability, severe
nicotine cravings, anxiety, anger, and increased appetite, among others (Julien et al.,
2008). The duration of these symptoms varies also, but individuals experience the most
severe symptoms within the first 2 weeks of abstinence (Hughes, Higgins, & Bickel,
1994). The combination of rapid tolerance to, dependence on, and withdrawal symptoms
from nicotine make smoking an exceptionally difficult behavior to change. Relapse is
common among those trying to quit and most individuals require multiple quit attempts
to achieve long-term abstinence (Hughes, Gust, Skoog, Keenan, & Fenwick, 1991).
Common Smoking Cessation Treatments
Since the Surgeon General’s publication on smoking and health in 1964,
extensive research, evaluation, and implementation of smoking cessation treatments have
been national health objective priorities. Most commonly used evidence-based smoking
cessation treatments fall into one of two broad categories: pharmacotherapies or
psychosocial therapies. The most commonly used pharmacotherapy is nicotine
replacement therapy (NRT), which is available in many over-the-counter forms and
works to reduce the withdrawal symptoms associated with smoking abstinence (Day,
2008). NRTs accomplish this, as the name suggests, by replacing smokers’ source of
nicotine (i.e., cigarettes) with nicotine from other sources (e.g., gum, transdermal patch,
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inhaler), gradually reducing nicotine levels over time until no nicotine delivery is
necessary; however, unlike nicotine administered through smoking, NRTs do not contain
high amounts of carcinogens and use nicotine levels significantly lower than those found
in cigarettes (Murray, Connett, & Zapawa, 2009). A recent meta-analysis of over 132
trials on NRT’s effectiveness found that NRTs increase the likelihood of smoking
cessation from 50 – 70% compared to placebo (Stead, Perera, Bullen, Mant, & Lancaster,
2008).
Other less common pharmacological treatments are the prescription drugs
bupropion and varenicline. Originally prescribed as an antidepressant (i.e., Welbutrin ®),
bupropion (marketed as Zyban® for smoking cessation) reduces nicotine withdrawal
symptoms. Although its pharmacological mechanism has not been identified, bupropion
inhibits dopamine and noradrenaline reuptake, and may attenuate reductions in these
neurotransmitters that occur during nicotine withdrawal (Roddy, 2004). Bupropion
treatment for smoking cessation is more effective than NRT, producing abstinence rates
roughly twice as high (Jorenby et al., 1999). Varenicline (marketed as Chantix ®), the
most recently FDA-approved pharmacological smoking cessation treatment, is not
derived from nicotine and is not an antidepressant but is classified as a partial nicotine
receptor agonist (Julien et al., 2008). Its success stems from its ability to relieve nicotine
withdrawal symptoms and reduce nicotine’s effects by allowing partial nicotine receptor
stimulation and by increasing dopamine levels. Compared to bupropion, varenicline is
significantly more effective in facilitating smoking abstinence, with rates approximately
1.5 times higher (Jorenby et al., 2006).
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Evidence-based psychosocial therapies are a prevalent smoking cessation
treatment option, especially among those for whom pharmacotherapy is contraindicated
(Vidrine, Cofta-Woerpel, Daza, Wright, & Wetter, 2006). Although the formats of the
interventions vary widely, many clinicians use a “5A” treatment, which consists of five
simple steps to encourage smoking cessation: Ask about tobacco use, advise to quit,
assess motivation to quit, assist in quit attempt, and arrange a follow-up (National
Institutes of Health [NIH], 2008). Strategies for assisting in quit attempts focus on
developing problem solving and skills training to identify high-risk relapse situations,
learning coping skills to reduce negative affect and urges to smoke, and providing
supplementary materials related to smoking cessation (e.g., list of withdrawal symptoms).
In addition, clinicians ensure intratreatment support and promote extratreatment support
from family members, friends, and others. For individuals not yet ready to stop smoking,
clinicians employ other techniques, such as motivational interviewing.
Psychosocial interventions generally are effective in helping individuals reach
long-term smoking abstinence, with long-term abstinence rates of 12-24% compared to
no treatment abstinence rates of 8-12 % (NIH, 2008). A number of variables may account
for this relatively wide range of long-term abstinence in psychosocial interventions, such
as the type and number of clinicians and the length and number of sessions. In a recent
meta-analysis (NIH), researchers found that interventions that include a physician and
multiple clinicians are more effective than a clinician alone. Additionally, researchers
detected a dose-response relationship between session length and number of sessions on
long-term abstinence, such that more and longer sessions led to higher abstinence rates.
Although psychosocial interventions and pharmacotherapies are effective by themselves,
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when combined, long-term abstinence rates improve greatly (e.g., 14.6 vs. 22.1%); thus,
the current guidelines recommend multicomponent treatments (i.e., at least one
psychosocial intervention plus pharmacotherapy).

CHAPTER 2
A Behavior-analytic View of Smoking
Behavior analysis is an empirical, science-based discipline that asserts that
behavior is orderly, lawful, and subject to objective analysis (Pierce & Cheney, 2004).
Central to a behavior-analytic approach is the belief that all behaviors, regardless of their
social acceptance, complexity, or species of the organism behaving, are the result of an
organism's interaction with its environmental contingencies. This interaction is best
represented by a four-term contingency (i.e., MO-SD-R-SR/ SP), in which some
environmental variable alters the value of a consequence or the frequency of the behavior
(motivating operation, MO) in a particular context (discriminative stimulus, SD), which
changes the future probability of responses (R) that have been followed by that
consequence (reinforcer or punisher, SR or SP; Cooper, Heron, & Heward, 2007). That is,
responses are selected (i.e., increased or decreased) by the consequences that follow them
under particular circumstances.
To apply the four-term contingency to smoking, consider an individual who has
just woken up from a night's rest. Because this individual has not smoked for some time,
his or her deprived state increases the value of a cigarette's effects (MO) and increases the
likelihood of behaviors that have led to cigarettes in the past. This deprivation also may
increase the saliency of discriminative stimuli (SD) that signal the availability of
cigarettes (e.g., lighters, smoking chair). After a series of chained behaviors (e.g., looking
for pack, taking out cigarette, lighting it), the individual inhales the smoke and smoking
is immediately reinforced by its consequences, which may be the addition of an
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appetitive stimulus (e.g., increased alertness), the removal or avoidance of an aversive
stimulus (e.g., headache from nicotine withdrawal), or both.
Implicit in the above example is that smoking is an operant that is acquired,
maintained, and strengthened through the reinforcing effects of nicotine (Higgins, Heil, &
Lussier, 2004). This conclusion is supported by a large number of studies in which
nicotine-dependent humans and nicotine-naïve nonhuman animals self administer
nicotine (for reviews see Foll & Goldberg, 2006; Rose & Corrigall, 1997). For example,
in Shoaib, Schindler, and Goldberg (1997), rats received intravenous injections of
nicotine for location-specific nose pokes on a fixed ratio (FR)-1 schedule (i.e., each
spatially-correct nose poke resulted in reinforcer delivery), with nose pokes to other holes
having no programmed consequence. Shoaib et al. found that nicotine naïve rats readily
self administered nicotine and continued self-administration as the reinforcement thinned
to an FR-5 schedule (i.e., every fifth nose poke resulted in reinforcer delivery). After
acquiring nicotine self-administration, rats underwent one of two extinction conditions:
Rats received a saline solution injection rather than nicotine or a presession injection of a
nicotine antagonist (mecamylamine). In both conditions, the rats' responding decreased
significantly compared to the initial nicotine self-administration sessions, demonstrating
that nose poking was maintained by the reinforcing effects of nicotine. Henningfield and
Goldberg (1983) found similar results in human smokers and nonsmokers using
intravenous nicotine and saline solutions in a concurrent FR-10 schedule (i.e., responses
were discrete and consequences were delivered for every tenth discrete response). These
studies suggest that humans and nonhuman animals are biologically susceptible to
nicotine's effects (i.e., nicotine is an unconditioned reinforcer) and that smoking is an
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operant behavior controlled by its consequences (Bigelow & Silverman, 1999). Other
characteristics of nicotine self-administration, such as similar response patterns and
response requirements to food or water as reinforcers, support these notions (Griffiths,
Bigelow, & Henningfield, 1980).
Because smoking is an operant behavior controlled in part by its consequences, it
lends itself easily to treatment through manipulation of the contingencies that maintain it
(Stitzer & Petry, 2006). One method to reduce smoking is through punishment
procedures, in which an individual (e.g., therapist, individual trying to quit) delivers a
stimulus (i.e., positive punishment) or removes a stimulus (i.e., negative punishment)
contingent on smoking. Powell and Azrin (1968) attempted the former by delivering
shocks of varying magnitude to human participants contingent on opening a pack of
cigarettes. As expected, they found a significant decrease in cigarette smoking, but
because of the aversive nature of the intervention, only 3 of 20 participants completed the
study. Therefore, it is unlikely that interventions using positive punishment will be
acceptable or used. Negative punishment is employed frequently in behavioral smoking
cessation treatments, but typically as a component of a more comprehensive intervention.
For example, smokers in Roll and Higgins (2000) earned monetary vouchers contingent
on abstaining from smoking that escalated in value for each consecutive day of smoking
abstinence (e.g., $3.00, $4.00, $5.00); however, if participants smoked, their next voucher
payment reset to the lowest value (i.e., smoking resulted in the removal of a highervalued voucher). Carefully planned and sparingly used punishment such as that in Roll
and Higgins can be socially acceptable and effective in reducing smoking, but because of
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potential negative side effects of punishment (e.g., aggression; Newsam, Favell, &
Rincover, 1983; van Houten, 1983), reinforcement procedures are preferred.
To comprehend how reinforcement procedures, which by definition increase
behavior, are implemented to reduce behavior (i.e., smoking), requires an understanding
of operants as choice (McDowell, 1988). Recall the earlier example, in which a four-term
contingency (MO-SD-R-SR /SP) explained an individual's interaction with the
environment that resulted in smoking. Although accurate and useful for discovering the
influencing variables of a specific behavior, this explanation is overly simplistic and
assumes that no other consequences exist in the individual's environment. Clearly, there
are a large number of sources of reinforcement contingent on behavior other than
smoking available that the individual could contact, such as brewing coffee, watching
television, or taking a shower; yet, smoking occurred to the exclusion of these
alternatives. This scenario demonstrates that smoking can be conceptualized as a choice;
behavior selected from a variety of alternative, concurrent, and competing behaviors that
can result in sources of reinforcement (Vuchinich & Heather, 2003).
The nature of how organisms distribute their behavior across concurrent sources
of reinforcement was first quantified by Herrnstein (1961). Using two pigeons as
subjects, Herrnstein arranged a two-key concurrent schedule, with each operating on
variable-interval (VI) schedules of food reinforcement (i.e., reinforcers were delivered for
the first response after a random average length of time since the previous reinforcer
delivery). During the procedure, the total amount of reinforcement available for pecks on
each key was held constant across sessions, but the intervals were manipulated using one
pair of equal schedules (VI-3s VI-3s) and three unequal schedules (e.g., VI-9s VI-1.5s).
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Herrnstein found that the pigeons' relative rates of responding equaled or matched the
relative rates of reinforcement. That is, whether the pigeons pecked the left or right key
depended on the relative rather than absolute rates of reinforcement. For example, during
a VI-3s VI-3s session, pigeons would distribute their pecks roughly equally across both
keys because each delivers food at the same rate. Whereas during a VI-3s VI-6s session,
pigeons would distribute roughly twice as many pecks on the VI-3s key than the VI-6s
key because it delivers food at twice the rate. This relation between response rates and
reinforcer rates is quantified as the matching law
R1 / (R1 + R2) = r1 / (r1 + r2)
(1)
where R1 and R2 represent response rates across two alternatives and r1 and r2 represent
the reinforcement rates on those alternatives (McDowell, 1988). Although the above
equation is suitable for settings in which multiple, readily identified alternatives exist
(e.g., two keys on VI schedules), it is not appropriate for settings in which there is a
single alternative (i.e., engaging in a target behavior or not). The latter is accounted for
easily by substituting response and reinforcement rates for a discrete second choice (R2
and r2 in Equation 1) with aggregates representing all extraneous responses and their
associated reinforcement rates. This produces
R / (R + Re) = r / (r + re)
(2)
where R and r refer to response and reinforcement rates of a target behavior (i.e.,
instrumental responding) and Re and re refer to total response and reinforcement rates of
behaviors other than the target behavior (i.e., extraneous responding). Because using
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response rates as dependent measures is not preferred in all cases (e.g., Conger & Killeen,
1974), the matching law is expressed occasionally in terms of time allocated to
alternatives, which accounts for behavior equally well as rate of responding (Baum &
Rachlin, 1969).
Since the emergence of the matching law over 40 years ago, researchers have
shown its utility in quantitatively accounting for significant amounts of variability in
choice (over 90%; Baum, 1979; McDowell, 1988). Also, the matching law's generality
has been extended substantially across various human and nonhuman animals, responses,
and reinforcers, in both laboratory and natural settings. Furthermore, several studies
revealed that known parameters of reinforcement other than rate, including magnitude or
amount (Catania, 1963), delay (Chung & Herrnstein, 1967), and quality (Hollard &
Davison, 1971), enter into the matching law to provide a comprehensive explanation of
choice. Taken together, these studies show that a particular behavior is more likely to
occur when reinforcement is richer (i.e., occurs at a higher rate), of larger magnitude,
more immediate, and of greater quality than reinforcement available for alternative
behaviors.
The matching law revolutionized operant theory in at least two major ways
(Vuchinich & Heather, 2003). First, Herrnstein's (1961) approach to understanding
choice behavior deviated from the generally accepted molecular view of behavior.
Molecular views focus on the controlling variables of particular instances of behavior,
whereas Herrnstein's molar view considers aggregated behavior extended over some
length of time (Pierce & Cheney, 2004). By demonstrating that meaningful relationships
could emerge from a molar interpretation, Herrnstein expanded the scope of operant
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analysis. A second and related contribution was the recognition of behavioral relativism.
Prior to the matching law, researchers investigated principles of reinforcement using
single responses, largely ignoring the influence of alternative sources of reinforcement.
Herrnstein's work shows definitively that the extent to which a behavior occurs depends
on other contingencies operating in the environment.
In addition to its conceptual advancements of an analysis of behavior, the
matching law supported the development of new therapeutic applications of
reinforcement (McDowell, 1988). Now, rather than manipulating directly the
contingencies of reinforcement associated with the target behavior (Equation 2, r),
reinforcement for alternative behaviors (Equation 2, re) could be targeted to indirectly
increase or decrease the target behavior. For example, to decrease the target behavior of
smoking (Equation 1, R1 ), one could increase reinforcement associated with other
therapeutic behaviors, such as exercise (Equation 1, R2). The addition of reinforcement
for a healthy alternative behavior decreases the relative reinforcing efficacy of smoking,
and behavior previously allocated to smoking decreases and is redistributed to exercise.
Alternative behaviors may be maintained by adding a contingent reinforcer, such as
social praise (i.e., positive reinforcement) or programming the removal or avoidance of
an aversive stimulus, such as a fine (i.e., negative reinforcement).
The above procedures and others like them in which reinforcement contingencies
are arranged to compete with those maintaining an undesirable behavior have been
validated empirically in controlled laboratory experiments investigating nicotine selfadministration and smoking in nonhuman animals and humans (for other drugs, see
Carroll, Bickel, & Higgins, 2001; for nicotine, see Perkins, Hickcox, & Grobe, 2000). For
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example, LeSage (2009) investigated the effects of providing a sucrose alternative to two
groups of rats trained to self administer nicotine. For both groups, an FI-3s was in effect
for nicotine administration, but the contingencies for sucrose delivery differed. The
differential-reinforcement-of-other-behavior (DRO) group received sucrose
administration contingent on engaging in any behavior but lever pressing for nicotine
administration for periods ranging from 40 – 160s. The fixed-time group (FT) received
sucrose administration noncontingently (i.e, independent of responding and based on a
specific, constant time interval) whose delivery was yoked to a rat in the DRO group.
Consistent with matching theory, both groups reduced nicotine self-administration
compared to baseline levels when the alternative reinforcer of sucrose was available. As
expected, rats in the DRO group reduced nicotine self-administration significantly more
than rats in the FT group. This finding suggests that applications in which reinforcement
is contingent on not using nicotine are most effective in reducing nicotine use. Bisaga,
Padilla, Garawi, Sullivan, and Haney (2006) found similar results with human
participants choosing between three puffs of a cigarette and monetary alternatives. The
researchers did not record a baseline measure of choice, but participants chose the money
option increasingly more as its magnitude increased from $0.5 - $3, showing that
providing monetary alternatives contingent on non-smoking behaviors can decrease
smoking.
Although brief, the review above provides rich empirical evidence of four general
operant principles of smoking, adapted from Higgins (1997): (a) smoking is an operant
behavior subject to analysis through the four-term contingency; (b) nicotine serves as an
unconditioned reinforcer, similar to food or water; (c) the extent to which smoking occurs
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is dependent on the contingencies of the particular environmental context; and (d)
providing alternative, non-nicotine sources of reinforcement can decrease smoking.
These principles form the foundation for a powerful behavioral smoking cessation
treatment known as contingency management.
Contingency Management: Description and Efficacy
Contingency management (CM) is a scientific, incentive-based behavioral
intervention, typically used for the treatment of substance abuse, including smoking (for
review see Petry, 2000). Based on core operant principles, CM procedures capitalize on
the fundamental laws that govern behavior by manipulating or “managing” directly or
indirectly the contingencies maintaining target behaviors involved in drug use (Higgins &
Silverman, 2008). In CM for smoking cessation (CMSC), the therapist or researcher
programs and implements artificial reinforcement contingencies for behaviors that are
incompatible with smoking or are consistent with related therapeutic behaviors. These
alternative contingencies are designed to compete with the natural contingencies that
maintain smoking, with the intention that the individual will choose the programmed
contingencies, thereby initiating smoking reduction, abstinence, or some other therapeutic
behavior. The ultimate goal of CMSC is to initiate and maintain behavior change until the
individual contacts the natural reinforcers associated with smoking cessation that sustain
long-term abstinence.
Essentially, CM involves DRO procedures in which putative reinforcers (e.g.,
vouchers, money) are provided when an individual can provide evidence of recent
smoking abstinence or reduction but are not provided when an individual provides
evidence of recent smoking or smoking above a specified level. A central feature that
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distinguishes CM from other smoking cessation treatments is its frequent monitoring of
smoking using objective (e.g., biochemical markers) rather than subjective (e.g., selfreport) measures (Stitzer & Petry, 2006). The use of frequent monitoring with
sophisticated measures ensures that individuals are rewarded only when a target behavior
is met but also allows researchers and therapists to track individual progress and respond
quickly to create a more individualized and effective treatment.
The efficacy of CM and its generality are well established for the treatment of
various substances (Bigelow & Silverman, 1999) among diverse populations
(Prendergast, Podus, Finney, Greenwell, & Roll, 2006). Abused substances other than
nicotine that have been effectively treated using CM include opioids (Petry, & Martin,
2002), alcohol (Petry, Martin, Cooney, & Kranzler, 2000), methamphetamines (Shoptaw
et al., 2005), cocaine (Higgins et al., 1994), marijuana (Budney, Moore, Higgins, &
Rocha, 2006) and benzodiazepines (Stitzer, Bigelow, & Liebson, 1979). In CMSC
studies, the populations treated consist of the mentally ill (Tidey, O'Neil, & Higgins,
2002), adolescents (Krishnan-Sarin et al., 2006), college students (Irons & Correia,
2008a), healthy adults (Stitzer & Bigelow, 1983), pregnant women (Higgins et al., 2004),
and methadone-maintained opioid users (Shoptaw et al., 2002). Although the majority of
CM studies focus primarily on arranging contingencies directly related to substance use,
some have used CM to increase therapeutic behaviors such as treatment attendance
(Carey & Carey, 1990) and meeting personal treatment goals (Iguchi, Belding, Morral,
Lamb, & Husband, 1997).
To date, three treatment-control meta-analyses have been conducted to evaluate
the effectiveness of CM for the treatment of substance use disorders. Lussier, Heil,
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Mongeon, Badger, and Higgins (2006) examined all studies, regardless of substance,
published from 1991-2004 that included voucher-based reinforcement therapy (VBRT), a
form of CM in which individuals receive vouchers exchangeable for goods or services
contingent on reducing or abstaining from substance use. Lussier et al. included 30
experimental studies in their analysis and found an overall medium effect size (r = .32)
and a slightly larger effect size for studies targeting nicotine (r = .47); however, the latter
findings should be interpreted cautiously as the number of inclusive studies was limited.
Prendergast et al. (2006) addressed this limitation by extending their meta-analysis' time
frame from 1970-2002 and by including all forms of CM (i.e., not just VBRTs). A total of
47 studies that were not limited by substance type comprised the meta-analysis, which
revealed an overall medium effect size (d = 0.42). Expressed in terms of treatment
success rates, groups in which CM was the primary treatment were 22% more successful
than controls. For the 11 studies targeting nicotine, the effect size was slightly lower (d =
0.31). These meta-analyses provide compelling evidence that CM is an efficacious
treatment for illicit and licit drug use.
Although Lussier et al. (2006) and Prendergast et al. (2006) highlight the efficacy
of CM, no comparisons were made between CM and other commonly used substance
abuse treatments. Recently, Dutra et al. (2008) conducted a comparative meta-analysis of
psychosocial treatments for substance use disorders from 1840-2005, including CM.
They found the largest treatment effect size for CM (d = 0.58) compared to four other
treatments. Moreover, CM produced the highest treatment retention rates (70.6%) of all
treatments included in the study. Despite these positive results regarding CM, Dutra et al.
compared only psychosocial treatments of illicit drugs. Because the researchers did not
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include smoking cessation treatments in their analyses, the extent to which these results
may generalize is unknown, but given the results of previous meta-analyses and direct
study comparisons (see below), it would not be unlikely that similar results would be
found for nicotine use.
To determine the differential efficacy of CM and pharmacological treatments for
smoking cessation, Tidey et al. (2002) examined NRT and CM among individuals with
schizophrenia. Using a within-subject repeated measures design and counterbalanced
assignment, participants experienced three conditions: CM with a transdermal nicotine
patch (CM + NRT), CM with a placebo patch (CM + P), and noncontingent
reinforcement with a placebo patch (NC + P). Each condition lasted 5 consecutive days
and was separated by a washout period in which participants could smoke as usual. Tidey
et al. found that participants reduced their smoking levels significantly from baseline and
submitted more consecutive abstinence samples during CM + NRT and CM + P weeks
compared to NC + P. There were no significant differences in smoking reductions
between the CM + NRT and CM + P conditions, indicating that CM was the treatment
component responsible for the reductions and that the addition of NRT to CM procedures
did not increase its efficacy. More recently, Glenn and Dallery (2007) compared the
short-term effects of a nicotine patch and CM on smoking; however, unlike Tidey et al.,
they used a nonclinical sample of heavy adult smokers. Across 4 weeks, participants
experienced the following conditions, which each lasted 5 days: baseline, 14mg nicotine
patch (NRT), CM, and return to baseline; treatment conditions were counterbalanced
across participants. Glenn and Dallery found that during CM, participants significantly
decreased their smoking (38%) relative to baseline weeks but did not significantly
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decrease their smoking during NRT relative to baselines. Moreover, during CM 24% of
the submitted samples met abstinence criteria compared to only 5% of those submitted
during NRT. These findings extend those of Tidey et al. to a nonclinical population and
provide further evidence that CM is more effective in initiating short-term smoking
abstinence compared to NRT.
Only two studies have made direct comparisons between CM and psychosocial
treatments for smoking cessation. Krishnan-Sarin et al. (2006) evaluated cognitive
behavioral therapy (CBT) and CM in a school-based program for adolescents.
Participants were assigned randomly to a CBT-only group or a CBT + CM group for 4
weeks, including weekends. Participants assigned to the combined group achieved
significantly higher smoking abstinence rates (one week: 76.7%; one month: 53%) than
those assigned to CBT alone (one week: 7.2%; one month: 0%). In another study,
Tevyaw et al. (2009) compared CM and motivation enhancement therapy (MET) along
with their placebos (noncontingent reinforcement control [NRC] and relaxation control
[RC], respectively) in a clinical trial for college student smokers. In a between-groups
design, participants were assigned to one of four conditions, each lasting 3 weeks: MET +
CM, MET + NRC, RC + CM, and RC + NRC. Tevyaw et al. found that treatments that
included CM were significantly more efficacious than those including NRC. Compared to
participants in NRC groups, participants in CM groups provided on average significantly
lower carbon monoxide levels (5.8 vs. 12.3 parts per million) more abstinent samples
(55.2% vs. 17.9%), and more consecutive abstinent samples (10.1 vs. 2.1 readings). Type
of psychosocial treatment (i.e., MET, RC) had no significant effect on any smokingrelated outcomes. These studies demonstrate not only that CM is an effective smoking
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cessation treatment, but also that compared to other commonly used treatments, CM may
be more successful in inducing smoking reduction and abstinence. Similar studies
comparing CM and psychosocial interventions for the abuse of other substances support
this conclusion (e.g., Rawson et al., 2006).
CMSC: Payment Magnitudes and Arrangements
Because of the nature of smoking (i.e., it is prevalent, legal, and individuals
attempting to quit are prone to quick relapse), CMSC is typically shorter and more
practical than CM studies investigating other drugs of abuse (Roll, Higgins, & Badger,
1996). As a result, smoking serves as a useful exemplar to identify key parameters of CM
procedures, such as the effects of payment magnitude. In one of the earliest CMSC
studies, Stitzer and Bigelow (1983) evaluated the effects of pay amount on smoking
reduction among healthy adults across 6 weeks. Participants were assigned randomly to
receive $0, $1, $5, or $10 contingent on reducing their smoking by 50% relative to
baseline. Stitzer and Bigelow found an orderly relationship between pay amount and
smoking reduction such that as pay amount increased smoking decreased. In a subsequent
study, Stitzer and Bigelow (1984) investigated the effects of pay amount on smoking
reduction using a sliding scale payment schedule. Participants earned varying amounts of
money contingent on smoking reductions over a 4-week period (maximum payments
ranged from $1.50 to $12.00), with larger reductions resulting in larger pay amounts.
Consistent with their previous findings, Stitzer and Bigelow found that participants
reduced their smoking more when pay amounts were higher. These findings and others
(e.g., Correia & Benson, 2006) suggest that when feasible, higher pay amounts or more
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valued goods (for voucher-based programs) should be implemented to produce potential
greater smoking reductions.
Another notable parameter identified through CMSC is the payment arrangement
for smoking reduction or abstinence (Roll & Shoptaw, 2006). Although researchers have
long been aware of the importance of reinforcement schedules on responding, this area
was not systematically studied within CM procedures until more recently. In 1996, Roll
et al. evaluated three different payment arrangements over the course of 5 days using
smoking as an exemplar. Participants were assigned randomly to one of three payment
arrangements: escalating magnitude of reinforcement, constant magnitude of
reinforcement, and noncontingent reinforcement. Payments for participants in the
escalating magnitude group began at $3.00 for the first negative sample and increased
$0.50 for each subsequent consecutive abstinence. For every third consecutive sample
indicative of abstinence, participants earned a bonus payment of $10.00. However, if
participants provided a positive sample, payment was not provided and reset to the initial
amount of $3.00 for the next session. Following three consecutive negative samples,
participants' payments returned to the value at which the reset occurred. Participants in
the constant magnitude group received a payment of $9.80 for every negative sample
without any resets or bonuses. Payments for participants in the noncontingent
reinforcement group were yoked to those in the escalating magnitude group. That is,
participants in the noncontingent group earned monetary reinforcement independent of
their smoking levels. Roll et al. found that participants in the response-contingent groups
(i.e., escalating and constant magnitudes) abstained from smoking significantly more than
those in the noncontingent group, but did not differ from each other. Although there were
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no significant differences between the response-contingent groups in terms of abstinent
samples submitted, participants in the escalating magnitude group did show significantly
less relapse following a brief period of abstinence compared to the constant magnitude
group. These findings demonstrate the influence of payment arrangements in CM
procedures and provide evidence that escalating magnitude rather than constant
magnitude arrangements may be most effective in CMSC.
To more specifically determine the effective components of this escalating
magnitude arrangement, Roll and Higgins (2000) conducted a within-subject systematic
replication of Roll et al. (1996) using three payment arrangements: escalating magnitude
with a reset contingency, escalating magnitude without a reset contingency, and constant
magnitude. During the escalating magnitude payment weeks, participants submitted
significantly more consecutive abstinent samples than during constant magnitude weeks.
There were no significant differences in smoking levels or number of abstinent samples
submitted between the escalating magnitude groups, but participants in the escalating
magnitude with reset contingency group were more likely to initiate and sustain
abstinence than those in the no reset group. Thus, inclusion of a reset contingency in
CMSC treatments may have some positive benefit on smoking outcomes.
CMSC: Contacting Reinforcement Contingencies
One struggle in implementing successful CMSC is determining the optimal
behavioral requirement(s) necessary to contact the reinforcement contingencies (Sigmon,
Lamb, & Dallery, 2008). That is, determining the amount one must decrease his or her
smoking in order to receive monetary payment or vouchers. The most common approach
in CMSC has been to set the reinforcement criterion from the outset, typically providing
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reinforcement only for those able to demonstrate complete smoking abstinence (e.g.,
Correia & Benson, 2006; Roll et al., 1996). However, this approach poses problems to a
large subset of individuals who, for a variety of reasons (e.g., low motivation to quit, high
nicotine dependency), are not able to abstain from smoking, even for relatively short
durations (Lamb, Kirby, Morral, Galbicka, & Iguchi, 2004). The result is that the main
goals of CM – that participants experience the rewards associated with smoking
abstinence and initiate and maintain that abstinence long-term– are never realized. An
additional concern of setting unrealistic reinforcement contingencies is that individuals
failing to meet these contingencies may withdraw from the treatment entirely and/or
become discouraged and be reluctant to initiate future quit attempts.
One viable alternative to using abstinence criterion determined from the outset is
to use percentile schedules of reinforcement1 (Galbicka, 1994; Lamb, Kirby, Morral et al.,
2004; Lamb, Morral, Kirby, Iguchi, Galbicka, 2004; Lamb, Morral, Kirby, Galbicka, &
Iguchi, 2005). In percentile schedules, reinforcement is delivered contingent on some
level of the target behavior (e.g., 50% of normal smoking) that is closer to the desired
behavior level (i.e., 0% of normal smoking) than some proportion of recently emitted
occurrences (e.g., last week’s smoking levels), and thus can be used to shape behavior.
For example, individuals may receive reinforcers contingent upon providing biological
verification of smoking levels that are lower than 8 of the 9 most recent samples or 16 of
the 19 most recent samples (both are examples of an 80th percentile schedule). Lamb,
Kirby et al. first implemented percentile schedules in a CMSC intervention among a
small sample of healthy adults who had no intentions to quit smoking. All participants
received reinforcement based on a percentile schedule, such that only carbon monoxide
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(CO) samples indicative of smoking below the median of the previous five samples
resulted in reinforcer delivery. In addition, participants were assigned randomly to a
constant or escalating magnitude payment arrangement (see Roll et al., 1996). Lamb,
Kirby et al. found that participants in both groups achieved significant reductions in
smoking as measured by CO levels and self report. Furthermore, participants in the
escalating magnitude condition achieved higher rates of overall abstinence. These results
replicated previous findings (e.g., Roll & Higgins, 2000) that showed escalatingmagnitude payments arrangements are more effective than constant magnitude payments,
but more importantly, demonstrated that percentile schedules of reinforcement are
feasible for use in CM.
In two follow-up studies, Lamb and colleagues (2004, 2005) investigated two
parameters of percentile schedules for CMSC. To determine the optimal percentile
schedule, Lamb et al. (2004) compared 10th, 30th, 50th, and 70th percentile schedules
among healthy adult smokers interested in quitting smoking. They found that over 90%
of participants in the 30th, 50th, and 70th percentile schedules were able to abstain
completely (i.e., CO ≤ 4 ppm) compared to 67% of participants in the 10th percentile
condition. These results indicate that percentile schedules of 30% or greater are most
effective for CMSC. In a second study, Lamb et al. (2005) compared the effects of the
number of samples used to set the percentile schedule criterion between two groups of
healthy adult smokers seeking smoking cessation treatment. Previous studies (Lamb,
Kirby et al., 2004; Lamb, Morral et al., 2004) used a nine-sample criterion, and so Lamb
et al. compared this to a novel four-sample criterion. They found no significant
differences in CO levels or percent meeting abstinence criterion between the nine- and
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four-sample windows. However, there was a trend towards lower CO and higher percent
meeting abstinence criterion for participants in the four-sample condition. Although not
conclusive, this study suggests that smaller sample windows for calculating percentile
schedules may be most effective.
CMSC: Behavioral Requirements
Another barrier to successful CMSC treatments is the relatively high behavioral
costs for participants that many interventions require (Sigmon et al., 2008). A crucial
characteristic of CM is the use of reliable and valid measures of smoking; however, due
to the short half-life of CO -- the most commonly used biochemical marker of smoking
used in CM studies -- measurements must occur frequently in order to obtain accurate
descriptions of smoking. In the past, the majority of CMSC studies have required that
participants make daily visits to a clinic or hospital in order to collect smoking
measurements (e.g., Lamb, Kirby et al., 2004). These demands can place large burdens
on participants for various reasons, such as the time and money lost during transportation
to and from the clinic. For example, Correia and Benson (2006) conducted a CMSC study
among a college student sample, which required two visits to a campus laboratory per
day, for 5 days per week, throughout the entire 3-week study (30 total visits). Although
the researchers found that the intervention was effective in reducing smoking among
college student smokers, only 39 participants (44%) completed the entire study.
Procedures that place high behavioral costs on participants increase the likelihood of
participant attrition, which is undesirable clinically and experimentally. Recently,
researchers have investigated and developed two areas that may have the potential to
reduce behavioral costs for individuals in CMSC treatments: (a) by using more accurate
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and precise biochemical measures of smoking and (b) by utilizing new technologies to
deliver CM treatments.
By employing more accurate and precise biochemical measures with longer half
lives than CO, researchers still would be able to validly detect smoking but would require
less frequent measurement from participants. One biochemical marker of smoking that
meets these specifications is cotinine, a nicotine metabolite found in plasma, saliva, and
urine (SRNT Subcommittee on Biochemical Verification [SBV], 2002). To investigate
the impact of reduced behavioral requirements on participant attrition by using cotinine
measures, Irons and Correia (2008a) conducted a 3-week brief abstinence test using a
college sample. By adding cotinine as the primary measure of smoking, Irons and Correia
limited measurements to once weekly, compared to the 10 weekly visits required in
Correia and Benson (2006). Furthermore, 100% of participants in Irons and Correia
attended all weekly sessions (i.e., no participant attrition). These results suggest that
improving biochemical measures of smoking may reduce participant visits and increase
participant retention, which may have positive impacts on treatment outcomes and costs.
Although using cotinine rather than CO measures is an effective method of
reducing behavioral costs incurred by the participant, there are several limitations
associated with its use. First, arranging abstinence contingencies early in treatment solely
using cotinine measures is inappropriate. Because of cotinine’s long half life relative to
CO, cotinine measures are unable to detect initial abstinence (SBV, 2002; i.e., measures
provided by a participant who abstains initially will still indicate smoking for several
days). To address this problem, researchers use multiple biochemical measures, either in
combination (Irons & Correia, 2008a) or at separate times during treatment when most
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appropriate (Higgins et al., 2004; e.g., initially using CO and later cotinine). Second,
cotinine measures do not provide valid measurements of smoking for participants using
nicotine replacement therapies (NRTs), whether planned as a treatment component or
otherwise. Finally, particular methods of analyzing cotinine (e.g., gas chromatography)
can be overly expensive and impractical outside of the laboratory setting.
Rather than targeting biochemical markers to reduce behavioral costs in CMSC,
some researchers have targeted the way in which biochemical samples are collected and
verified (Sigmon et al., 2008). Specifically, Dallery and colleagues (2005, 2007)
developed an internet-based data collection system that does not require visits to clinics
or hospitals to measure participants’ smoking levels. In this system, participants receive a
laptop computer, web camera, and a CO monitor to use and install in their homes. From
their homes, participants email CO video samples twice daily (separated by 8 hours or
more) via a web camera to the researchers, who view and confirm the readings and
deliver reinforcers electronically (e.g., online vouchers). Using this internet-based
system, Dallery and colleagues obtained perfect participant retention (i.e., no participants
left the 4-week studies), high sample submission rates (> 93%), and produced abstinence
rates similar to other CMSC studies. Others have replicated these findings (e.g., Glenn &
Dallery, 2007; Reynolds, Dallery, Shroff, Patak, & Leraas, 2008), suggesting that an
internet-based method of CMSC is feasible and effective.
Despite the success of an internet-based model, significant barriers to its more
widespread adoption exist, mainly concerning additional treatment costs (i.e., above and
beyond a non-internet-based approach) for large numbers of CO monitors, laptop
computers, and web cameras, which may be impractical. However, these costs may be
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more easily justified among individuals in particular subpopulations for whom behavioral
costs (e.g., money, transportation) pose greater challenges to successful smoking
cessation treatment, such as rural smokers (Stoops et al., 2009).
An additional method to reduce behavioral requirements for participating in
CMSC is to incorporate treatment in settings in which frequent smoking measurements
would be minimally invasive and easily accessible. Given that the average American
spends 30 or more hours each week working and that the vast majority of Americans
work outside of the home, the workplace may be an ideal location in which to study
further and potentially disseminate CMSC treatments (Donatelle et al., 2004; United
States Bureau of Labor Statistics, 2008, 2010). Furthermore, there are several benefits to
implementing CMSC within the workplace that may facilitate its adoption and its
efficacy: (a) CM approaches may appeal to employers interested in improving their
employees’ health, which in turn may increase productivity and reduce health insurance
premiums, (b) employees may be more likely to enroll in workplace programs that offer
incentives, such as CM, (c) delivery of vouchers or payments may be made easier
through already existing payroll systems, and (d) a workplace may encourage new social
support systems or the strengthening of current social support systems with coworkers.
Even with these numerous potential advantages, few studies have investigated the effects
of CMSC within the workplace.
Rand, Stitzer, Bigelow, and Mead (1989) were among the first to study directly
the effects of CMSC within the workplace. Using a between-groups design, hospital
employees were assigned to one of three conditions: CM with frequent monitoring of
smoking (FS), FS, and infrequent monitoring of smoking (IS). Rand et al. found that
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participants in the CM with FS group maintained smoking abstinence significantly longer
than those in the FS and IS group; there were no differences in smoking abstinence
outcomes between the FS and IS group. Although 11 of the total 51 participants (78%)
dropped out of the study within 6 months, exit interviews confirmed that these decisions
were due to health problems or job relocations, not to the treatment itself. These findings
show that regardless of smoking monitoring frequency, participants receiving payments
contingent on smoking abstinence have significantly better smoking cessation outcomes.
Moreover, these results demonstrate the feasibility of CMSC treatments within the
workplace. Other researchers have found similar results (Stitzer & Bigelow, 1983, 1985),
but were not concerned particularly with the impact of study setting on smoking
outcomes.
Since Rand et al. (1989), no researchers have published any studies focusing
specifically on the implementation of CMSC within the workplace, but extensive
research has been conducted on incentive-based smoking cessation workplace programs
(Donatelle et al., 2004; see Matson, Lee, & Hopp, 1993 for review). This broader
category of smoking cessation treatments differs from CM approaches in several
important aspects in that most: (a) do not employ advanced methods (e.g., shaping,
complex payment arrangements), (b) generally have less experimental control, (c) are not
based on psychological learning theory (i.e., operant conditioning), and (d) are included
typically only as a small part of more comprehensive smoking treatments (e.g.,
incentives, counseling, and education as one treatment package). These differences, along
with variations across studies regarding definitions of smoking abstinence (e.g., self
report vs. biochemical measures), treatment intensity and duration, and others preclude
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any definitive conclusions on the effects that contingent reinforcement may have on
smoking levels within the workplace.

CHAPTER 3
The Current Study
Although the current study included only smoking as its target behavior, the
issues addressed were not necessarily specific to smoking and may generalize to
applications of CM for other substances and behaviors. In the current study, I addressed
two barriers to the widespread adoption and implementation of CMSC. First, I assessed
the efficacy of a novel payment schedule designed to ameliorate past problems involving
response requirements. Typical payment arrangements in CMSC require individuals to
abstain completely to earn payment; however, large numbers of individuals are not able
to meet this criterion and as a result, fail or leave treatment. An alternative to abstinencecontingent payment schedules is to reinforce gradual reductions in smoking (i.e., shaping)
over extended periods of time. Although shaping addresses problems involving
unrealistic response requirements, not all individuals are incapable of abstaining from
smoking early in treatment and these individuals may actually benefit from abstinencecontingent payment arrangements. Additionally, requiring individuals to reduce smoking
gradually may involve higher monetary and behavioral costs, for researchers and
participants. A potential solution to these problems may be to combine abstinence- and
reduction-contingencies in one payment schedule. Providing payments for smoking
reduction and abstinence will allow for more individualized treatment and may be more
efficient than abstinence or shaping payment arrangements alone.
Consistent with previous research on effective payment arrangements, the novel
payment arrangement for the current study provided abstinence payments that escalated
in magnitude across weeks. Payments for smoking reduction decreased in magnitude
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across weeks, with the intention that the relative reinforcing value of abstinence to
reduction would become greater throughout treatment. These payment schedule
arrangements may facilitate complete smoking abstinence in later weeks among
participants who were first able to reduce but not abstain from smoking.
I expected that when the novel payment contingencies were present, smoking
levels would significantly decrease, relative to periods in which the novel payment
contingencies were absent.
Second, I implemented the current study within a workplace setting with the goal
of reducing behavioral costs incurred by participants. The majority of previous CMSC
studies required participants to meet frequently with the research team, often at
inconvenient locations (e.g., clinics). As a result of such impractical designs, many
participants miss treatment sessions or remove themselves from the treatment completely.
By employing CM for smoking cessation in the workplace, where occasional smoking
measurement would be relatively noninvasive and accessible, behavioral costs may
decrease. Such an outcome may improve participant retention and increase CM’s
effectiveness. Furthermore, because so few studies have examined CM within the
workplace, the current study provided important information on its feasibility and
acceptance in non-research settings.
I expected that because implementing CMSC within a workplace would reduce
the behavioral costs incurred by the participants, participant attrition would not occur.
Method
Participants
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Sample size considerations were made based on an a priori power analysis using
GPOWER software (Erdfelder, Faul, & Buchner, 1996). Using a medium effect size
based on a meta-analysis of CM for nicotine use (d = .31; Prendergast et al., 2006), an
ANOVA repeated measures a priori power analysis indicated that 16 participants would
be necessary for adequate power (.80) at an alpha level of .05.
Participants were 9 nonstudent staff members at James Madison University
(JMU). They were recruited through bulk email announcements sent to all JMU staff,
indicating that individuals over the age of 18 might be eligible to enroll in a smoking
cessation program during which they would have the opportunity to earn monetary
compensation. Interested staff completed an online screener, which was used to collect
demographic information, information related to characteristics of smoking behavior,
current or planned involvement in structured smoking cessation programs, and
willingness to provide biological samples to verify smoking status. Staff who self
reported smoking at least eight cigarettes per day, who were not involved in a structured
smoking cessation program, and who were willing to provide biological samples to verify
smoking status were eligible for this study. Eligible staff received a follow-up email,
which included a basic description and timeline of the study, time required for
participation, maximum amount of monetary compensation available, and an invitation to
attend one of multiple intake sessions.
Measures
Self-report measures. All self-report data were collected via online surveys.
Demographics questionnaire. This questionnaire was used to assess participant
characteristics, such as age, gender, and ethnicity (see Appendix A).
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Smoking Behavior Questionnaire (SBQ). This questionnaire was used to assess
information on smoking history; motivation to quit smoking; previous attempts to quit
smoking; and past, current, and future plans to engage in an active smoking cessation
program (see Appendix B).
Hooked on Nicotine Checklist (HONC; O’Loughlin, Kishchuk, DiFranza,
Tremblay, & Paradis, 2002). This checklist was used to assess level of tobacco
dependence based on 10 “yes” or “no” items that measure loss of autonomy (see
Appendix C). Loss of autonomy is a symptom characterized by decreased self-control
and compulsion, both of which are consistent with clinical descriptions of substance
dependence (Wellman et al., 2006). Scores are computed by adding the number of items
marked “yes” with higher scores corresponding to higher dependence. The HONC’s
psychometric properties and correlates with other smoking variables have been evaluated
among adults and adolescents (Wellman et al.; DiFranza et al., 2002). The HONC has a
one-factor structure with all items loading above .70, high internal consistency (α = .83 .94), and correlates significantly with a variety of smoking characteristics (e.g., smoking
frequency, level, duration, age of onset).
Fagerstrom Test for Nicotine Dependence (FTND; Heatherton, Kozlowski,
Frecker, & Fagerstrom, 1991). This 6-item questionnaire was modified from two earlier
versions of the Fagerstrom Tolerance Questionnaire (Fagerstrom & Schneider, 1989;
Prokhorov, Pallonen, Fava, Ding, & Niaura, 1996; see Appendix D) and is designed to
assess nicotine dependence of tobacco smoking. Specifically, the FTND assesses
dependence as measured by an individual’s compulsive smoking behavior, defined in
terms of nicotine withdrawal and craving. Items are dichotomous and are scored on a 10-

36
point scale, with higher scores corresponding to higher dependence. Despite its use in
most smoking cessation research and clinical settings, studies on the psychometric
properties of the FTND have produced inconsistent identification of its factor structure
(one-factor vs. two-factor; Wellmen et al. 2006; Radzius et al., 2003, respectively) and
poor internal consistency (α = .57 - .72). Furthermore, some researchers criticize its lack
of sensitivity and unclear interpretation; however, the FTND does correlate with smoking
characteristics (e.g., smoking levels) and may be predictive of long-term abstinence
(Breslau & Johnson, 2000). Because of its psychometric limitations, the FTND was
included primarily to allow for comparison with previous studies, which frequently report
this measure.
Wisconsin Smoking Withdrawal Scale (WSWS; Welsh et al., 1999). This 28item questionnaire was developed to assess severity and type of smoking withdrawal
symptoms (see Appendix E). Items consist of statements related to clinical symptoms of
smoking withdrawal (e.g., “I have felt impatient”) and are rated on a 5-point scale (1 =
strongly disagree, 5 = strongly agree). The WSWS provides an overall withdrawal score
(range = 0 [no withdrawal] – 140 [extreme withdrawal] and scores for each of its 7
subscales, which reflect clinical symptoms of nicotine withdrawal: anger, anxiety,
sadness, concentration, craving, sleep, and hunger (APA, 1994). Internal consistency for
measuring overall withdrawal is high (α = .90 - .91), whereas subscale internal
consistencies are slightly lower (α = .75 - .93). Additionally, overall measures on the
WSWS are predictive of smoking cessation outcomes (Welsch et al.)
Contemplation Ladder (CL; Biener & Abrams, 1991). Based on the
transtheoretical model of health behavior change, the CL was used to assess readiness to
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consider smoking cessation (see Appendix F). The CL consists of 10 “rungs”, which are
anchored with statements indicating gradually increasing levels of motivation to quit
smoking (e.g., “No thought of quitting” to “Taking action to quit”), with higher scores
representing greater motivation. Although this measure is not predictive of biochemically
verified smoking abstinence, it is predictive of future attempts to begin smoking cessation
and correlates significantly with the frequency of previous quit attempts and other
smoking change measures (Amodei & Lamb, 2004).
Daily Tobacco Report (DTR). This questionnaire was used to assess average
number of cigarettes smoked since last session, tobacco use over the last 24 hours, and
time since most recent use (see Appendix G). The DTR includes cigar and chewing
tobacco products in addition to cigarettes.
Biological measures.
Expired breath carbon monoxide (CO). BreathCO (Vitalograph Inc., Quivira,
KS), a portable breath CO reader, was used to verify smoking behavior (see Appendix
H). Expired breath CO in parts per million (ppm) has been established repeatedly as a
valid and reliable index of cigarette smoking, and correlates highly with other biological
markers indicative of recent smoking including nicotine and cotinine found in plasma,
saliva, and urine (Jarvis, Tunstall-Pedoe, Feyerabend, Vesey, & Saloojee, 1987), and in
plasma carboxyhemoglobin levels (Jarvis, Belcher, Vesey, & Hutchison, 1986). Selfreport measures such as number of cigarettes smoked per day (Abueg, Colletti, & Kopel,
1985), duration of smoking (Deveci, Deveci, Azik, & Ozan, 2004), time since smoking
last cigarette (Schmitz, Rhoades, & Grabowski, 1995), and depth of inhalation (Rea,
Tyrer, Kasap, & Beresford, 1973) also correlate highly with expired breath CO. Measures
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of expired breath CO have been used to distinguish self-identified nonsmokers and
smokers with high sensitivity (90%) and specificity (83% - 89%); however, the optimal
cut-off levels have varied across studies (range = 6ppm – 10.5ppm; Jarvis, TunstallPedoe et al.; Deveci et al.). Rough estimates of expired breath CO levels across differing
types of smokers indicate that, in general, light to moderate smokers have levels between
8 and 15 ppm and heavy smokers have levels between 15 and 40 ppm (Jarvis, Belcher et
al.,). Although expired breath CO is a relatively accurate measure (± 3ppm) of recent
smoking (6-8 hours), it is not as sensitive as other methods (e.g., urine and salivary
cotinine) but is the most common biochemical measure in CMSC. Unlike other methods,
obtaining expired breath CO is noninvasive, cost-effective, provides immediate results,
and its use is not constrained to a laboratory environment.
Urine cotinine. As a secondary measure, urine samples were analyzed to detect
nicotine and its principle metabolite, cotinine (see Appendix I). Unlike nicotine, which
has an elimination half-life of approximately 2 hours, cotinine has an elimination half-life
of 20 hours (Gilbert, 1993), allowing for more extended detection. Moreover, cotinine
levels are reliable and constant throughout most of a smoking day. Numerous studies
have demonstrated that urinalysis of cotinine is a valid and acceptable indicator of
smoking behavior (e.g., Murray, Connett, Lauger, & Voelker, 1993; Parker et al., 2002),
and correlates with other biological measure of recent smoking such as cotinine found in
plasma and saliva; nicotine found in plasma, saliva, and urine; expired breath CO and
plasma carboxyhemoglobin (Jarvis, Tunstall-Pedoe et al., 1987); and self-reported
number of cigarettes smoked per day (Perez-Stable, Benowitz, & Marin, 1995). Of all
biological measures of smoking, urine cotinine is the most sensitive (99%) and specific
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(97%) in discriminating smokers and nonsmokers (Gilbert). Immunoassay test strips
(ITS; NicCheck™ I; Mossman Associates, Blackstone, MA) were used, which provided
semiquantitative analyses of cotinine levels over the last 5-7 days. Studies on
NicCheck™ I strips have validated their utility and ease of use in measuring smoking
(Bernaards, Twisk, van Mechelen, Snel, & Kemper, 2004; Lesichow, Merikle, Cook,
Newman, & Muramoto, 1999). ITS scores and strip colors range from 0 (white) to 14
(dark pink), with 0 representing no smoking over the last 5 -7 days and 14 representing
very heavy smoking. When possible, ITS strip colors were independently reported by at
least two members of the research team. In instances when there was rater disagreement
in strip color scores, an average of the scores was recorded.
Procedure
I implemented a 6-week ABAB withdrawal design, including 1 week of
intake/baseline, 3 weeks of CM, 1 week of return to baseline, and 1 week of return to
CM. All monetary payments (attendance- and smoking-contingent) made available
throughout the study were added to participants’ bimonthly university paychecks. Over
the 6-week period, participants had the opportunity to earn $72 contingent on attending
all sessions and providing the required measures and $157 contingent on complete
abstinence from smoking for all sessions, for a total of $229. Raffle tickets were entered
into a drawing for a $75 VISA® check card, which occurred following completion of the
study; participants had the opportunity to earn 16 raffle tickets throughout the study. At
each session, participants were shown a progress report, which included information
about their recent smoking behavior and money earned. If participants failed to attend
more than one session, they were removed from the study.
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Intake/Baseline (Week 1). Staff who fulfilled the intake inclusion criteria met
with a member of the research team on campus in a psychology laboratory room at an
agreed upon time. At this session, a member of the research team verified that potential
participants smoked more than eight cigarettes per day, were not engaged in a structured
smoking cessation program or taking medication to quit smoking, and were willing to
provide biological samples. Participants were reminded that the biological measurements
detect only nicotine and CO. If participants met self-report inclusion criteria, they
provided informed consent and an expired breath CO sample, which must have been >
10 ppm to be eligible for enrollment. This inclusion CO level represents moderate
smoking levels and was selected as a cut-off to approximate the highest value used to
distinguish smokers and nonsmokers (Jarvis, Belcher et al., 1986). Next, the researcher
gave an overview of the study and answered any questions before obtaining informed
consent for full enrollment. Participants subsequently completed the following self-report
measures: demographics questionnaire, SBQ, HONC, FTND, WSWS, CL, and DTR.
Before leaving, participants were told that they earned $10 and that if they returned in 2
days (Baseline) and provided self-report and biological measures, they would earn $20,
regardless of their smoking levels.
During the baseline session, participants completed the DTR and provided
expired breath CO and urine samples. Before the end of the session, the researcher
described in detail the contingencies for the next 3 weeks (CM) and answered any
questions.
Contingency Management (CM; Weeks 2-4). During the 3 CM weeks,
participants met with a member of the research team twice weekly (Monday – Friday).
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The time and location of these meetings were individualized for each participant. That is,
participants had the option of meeting at the on-campus psychology laboratory, their
workplace, or some other agreed upon site. One of the two weekly meetings was held at a
constant date and time (planned), whereas the other meeting was not (surprise). At
surprise sessions, participants were notified of a session by phone 15 minutes prior, and
met a researcher at a prearranged location or the researcher came to the participant’s
workplace. Surprise sessions were included to discourage participants from smoking
irregularly in order to maximize payments (i.e., if all sessions were planned, a participant
could shift smoking patterns in ways that make smoking undetectable in order to earn
money without actually decreasing smoking).
Planned session. During planned sessions, participants provided expired breath
CO and urine samples and completed the DTR and WSWS. After the urinalysis was
complete, participants were told whether or not they met reduction or abstention criteria
and the accompanying payment (see below). Participants were reminded of the upcoming
contingencies, and regardless of smoking levels, all participants who completed the
required measures received $2 for their time. Planned sessions lasted no longer than 20
minutes.
Payments and reduction/abstention criteria. Reduction criteria for planned
sessions required that all of the following were met: (a) 30% reduction in expired breath
CO levels (taken from average of previous two sessions), (b) maintenance or decrease in
urine cotinine levels from previous session, and (c) decrease in self-reported number of
cigarettes smoked. Payments contingent on meeting reduction criteria across the 3 CM
weeks were held constant at $5 and one raffle ticket. Abstention criteria for planned
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sessions required that all of the following were met: (a) expired breath CO levels < 4
ppm, (b) maintenance or decrease in urine cotinine levels, and (c) self-reported number of
cigarettes smoked was 0. Payments contingent on meeting abstention criteria across the 3
CM weeks were held constant at $18 and two raffle tickets.
Surprise sessions. During surprise sessions, participants provided expired breath
CO samples and completed the DTR. After completing these measures, participants were
told whether they met reduction or abstention criteria for the sessions and the
accompanying payment (see below). Participants were reminded of the upcoming
contingencies, and regardless of smoking levels, all participants received $1 for their
time. Surprise sessions lasted no longer than 5 minutes.
Payments and reduction/abstention criteria. Reduction criteria for surprise
sessions required that the following were met: (a) 30% reduction in expired breath CO
levels (taken from average of previous two sessions) and (b) decrease in self-reported
number of cigarettes smoked. Payments contingent on meeting reduction criteria
decreased across the 3 CM weeks as follows: $8 during the first week, $4 during the
second week, and $2 during the third week. Each reduction payment included a raffle
ticket across all 3 CM weeks. Abstention criteria for surprise sessions required that the
following were met: (a) expired breath CO levels < 4 ppm and (b) self-reported number
of cigarettes was 0. Payments contingent on abstention criteria increased across the 3 CM
weeks as follows: $15 the first week, $20 the second week, and $25 the third week.
Return to Baseline (Week 5). During the return to baseline week, participants
met twice with the researcher. At the first session, participants provided expired breath
CO and urine samples and completed the SBQ, HONC, FTND, WSWS, CL, and DTR.
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At the second session, participants provided expired breath CO and urine samples and
completed the DTR, and the researcher explained the contingencies for the final study
week. Participants earned $10 and $20 for completing all required measures at the first
and second sessions, respectively.
Return to Contingency Management (CM; Week 6). The return to CM week
was identical in procedure to Weeks 2-4, but payments reflected the contingencies of
Week 4. At the planned session, participants earned $5 for reduction, $18 for abstention,
and $2 for completing the measures. At the surprise session, participants earned $2 for
reduction, $25 for abstention, and $1 for completing the measures. At the participants’
final session, researchers answered any questions about their involvement in the study
and made available additional resources for smoking cessation (see Appendix J).
Participants were told that an email would be sent to the winner of the raffle within the
next 2 weeks.
Results
Consistent with theoretical and clinical behavior analytic approaches, I analyzed
all data at the individual level (see Barlow, Nock, & Hersen, 2009 for a full discussion of
the advantages and disadvantages of this approach). Visual analysis (Cooper et al., 2007)
was used to determine the extent to which behavior changed as a result of the
experimental manipulation (i.e., CM) for the primary dependent smoking measures –
expired breath CO, urine cotinine, self-reported number of daily cigarettes smoked since
the previous session, and self-reported time since last smoking. Specifically, variability,
level, and trend were assessed within and across conditions when possible to detect any
meaningful changes in individuals’ smoking. In instances in which multiple responses
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were given for self-report items (e.g., number of cigarettes smoked since previous session
= 15-17), an average of the values was used. Although originally planned, inferential
statistical tests of significance as supplemental evidence were not used due to the small
sample size and associated low statistical power.
In total, 61 individuals responded and completed the initial smoking behavior
screener, and approximately 40 individuals met the study eligibility criteria. Of these
individuals, who were provided a brief description of the study and were invited to
participate, 12 scheduled and attended the intake session. Ultimately, 9 participants
qualified and enrolled in the study. For the 3 individuals who attended the intake session
but did not qualify for enrollment, 2 did not provide sufficiently high expired breath CO
readings, and 1 reported current use of nicotine replacement therapy. Of the 9
participants, six (67%) completed the entire study. Only data for those participants who
completed the entire 6-week study are reported.
General Description of Sample
All participants were Caucasian middle-aged women 42 – 59 years old (M =
48.4), with the exception of Participant 15, who was 28 years old, and Participant 8 who
was male. All participants reported smoking 7 days per week, began smoking as
adolescents, and expressed at least some desire to quit smoking. Four of the six
participants (Participants 3 and 15 being the exceptions) had attempted to quit smoking at
least once in their lifetime (M = 5.7 attempts, range = 1 - 15), and reported various
cessation methods including joining a support group, gradually reducing smoking levels,
referring to educational materials, enrolling in self-help programs, quitting with a friend,
and taking medications. All participants who had made previous attempts had tried
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quitting cold turkey. Five of the six participants showed symptoms of moderate to severe
nicotine dependence as demonstrated on the HONC (M = 8.6, range = 7 – 10) and FTND
(M = 5.6, range = 3 – 7). Participant 15 provided little evidence of significant nicotine
dependence (HONC = 4, FTND = 0).
Participant 3
Biological measures. Figure 1 shows the expired breath CO levels across all
condition weeks. During baseline, her CO levels dropped substantially at Session 2
following intake. Her CO levels throughout CM Weeks 2 – 4 were consistently lower
than the baseline mean but were still similar or slightly less than Session 2’s CO levels.
During the CM condition, her CO levels showed a minor downward trend and were
relatively stable. Following removal of the contingencies, her CO levels increased
slightly then dropped to nearly 0 at the next session. Upon reinstating CM for the final
week, her CO increased, similar to levels during CM Weeks 2 – 4. Of the 8 sessions for
which monetary compensation could be earned, Participant 3 met reduction CO criterion
for 1 (12.5%) and abstention CO criterion for 3 (37.5%).
Figure 2 shows the urinalysis scores across all condition weeks. Her urinalysis
scores at intake indicated high levels of smoking; however, her urinalysis score for
Session 2 decreased roughly 20%. On the first session of CM Weeks 2 – 4, her urinalysis
score was substantially lower than both urinalysis scores during baseline, but urinalysis
scores at Sessions 6 and 8 returned to baseline levels. During the first return to baseline
session, her urinalysis score changed little from Sessions 6 and 8, but decreased to its
lowest level at Session 10. Following reinstatement of CM, her urinalysis score increased
to levels similar to those of Sessions 6 and 8, but slightly lower than those for her first
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baseline week. Of the 4 sessions for which monetary compensation could be earned
contingent on urinalysis scores, she met reduction/abstention criterion on 2 (50%).
Self-report measures. Figure 3 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. Following
intake, her daily number of cigarettes smoked decreased 50.0% at Session 2. During CM
Weeks 2 – 4, her mean daily number of cigarettes smoked was substantially less than that
during the baseline session; however, CM Weeks 2 – 4’s values were similar to those
reported at Session 2.Throughout CM Weeks 2 – 4, her daily number of cigarettes
fluctuated slightly with no apparent trend. Upon removal of the contingencies, her daily
number of cigarettes decreased slightly from those of CM Weeks 2 -4. When CM was
reintroduced in Week 6, her daily number of cigarettes smoked increased slightly to
values within the range of those reported during CM Weeks 2 – 4. Of the 8 sessions for
which monetary compensation could be earned, Participant 3 met self-report reduction
criterion for 5 (62.5%) and abstention CO criterion for 0 (0.0%).
Figure 4 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. Time since last smoking increased to a large degree from
intake to Session 2 during the initial baseline. When CM was introduced during Weeks 2
– 4, time since last smoking changed little from Session 2 but remained within ranges
reported during baseline. Across CM Weeks 2 – 4’s sessions, time since last smoking
varied slightly with an observable small upward trend during Weeks 3 and 4. When the
contingencies were removed for Week 5 and reinstated for Week 6, her time since last
smoking varied significantly, with two sessions (Sessions 10 and 12) well above
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previously reported times, whereas Sessions 9 and 11 were consistent with those reported
during the initial baseline and CM Weeks 2 – 4.
Attendance and earnings. Participant 3 attended all 12 sessions of the study. Of
the 8 sessions for which she could earn monetary compensation contingent on smoking,
she met all reduction criteria twice (25.0%) and did not meet all abstention criteria for
any session (0.0%). In total, she earned $10/2 raffle tickets for decreasing her smoking
and $72 for attending sessions and completing all required measures.
Participant 8
Biological measures. Figure 5 shows the expired breath CO levels across all
condition weeks. During the baseline week, his CO levels fell significantly (75%
decrease) during Session 2 relative to intake. Following implementation of CM, his CO
level increased above Session 2’s value, but much lower than intake. Sessions 3 – 5
showed a declining trend with little variability, eventually reaching a CO level less than
that of Session 2. His CO for Sessions 6 – 8 increased to levels slightly less than his
average baseline and was stable. When contingencies were subsequently withdrawn, his
CO levels increased slightly above CM Week’s 2 – 4’s levels. For Week 6, when CM
was reinstated, his CO levels increased relative to the previous baseline, at levels higher
than all previous sessions excluding intake. Of the 8 sessions for which monetary
compensation could be earned, Participant 8 met CO reduction criterion for 1 (12.5%)
and abstention CO criterion for 1 (12.5%).
Figure 6 shows the urinalysis scores across all condition weeks. Urinalysis scores
during baseline were stable and indicative of light smoking levels. When contingencies
were implemented, urinalysis scores increased significantly at Session 3, but stabilized at
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Sessions 5 and 8 at levels below those of baseline. The sudden increase in his urinalysis
scores at Session 3 was likely a result of chewing tobacco use, which he self reported
using at times in place of smoking at Sessions 2 and 3. The use of chewing tobacco in
place of smoking may also account for the sharp decline in CO levels from Session 1 to 2
(see Figure 5). During the return to baseline, his urinalysis scores increased to levels
above the initial baseline week and to levels much higher than those of Sessions 5 and 8.
When CM was reintroduced during Week 6, his urinalysis score remained at levels
consistent with those of the previous baseline condition. Of the 4 sessions for which
monetary compensation could be earned contingent on urinalysis scores, he met
reduction/abstention criterion on 2 (50.0%).
Self-report measures. Figure 7 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. During baseline,
there was a small decrease in daily number of cigarettes smoked from intake to Session 2.
Upon introduction of CM, the daily number of cigarettes smoked decreased sharply,
nearly to zero, for Sessions 3 and 4, but increased and stabilized during the remaining
sessions of CM Weeks 2 – 4. Despite this increase, the daily number of cigarettes smoked
was still significantly less than baseline levels. When CM was withdrawn during Week 5,
the daily number of cigarettes smoked did not change notably. During the final CM week,
the daily number of cigarettes smoked increased slightly than decreased to levels similar
to CM Weeks 2 – 4 for the final session. Of the 8 sessions for which monetary
compensation could be earned, Participant 8 met self-report reduction criterion for 4
(50.0 %) and abstention CO criterion for 0 (0.0%).
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Figure 8 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. During the baseline week, time since last smoking increased
drastically from intake to Session 2. Again, this increase is likely attributable to his use of
chewing tobacco between Sessions 1 and 2. During CM Weeks 2 – 4, time since last
smoking remained relatively stable, with the exception of Session 7, and increased
relative to baseline (omitting Session 2 as a comparison). Time since last smoking
changed little when the contingencies were removed during Week 5 and when they were
last reimplemented at Week 6.
Attendance and earnings. Participant 8 attended all 12 sessions of the study. Of
the 8 sessions for which he could earn monetary compensation contingent on smoking, he
met all reduction criteria once (12.5%) and did not meet all abstention criteria for any
session (0.0%). In total, he earned $8/1 raffle tickets for decreasing his smoking and $72
for attending sessions and completing all required measures.
Participant 11
Biological measures. Figure 9 shows expired breath CO levels across all
condition weeks. During baseline, her CO levels were relatively stable and indicative of
moderate smoking. Upon introduction of CM, her CO levels reduced significantly for all
sessions relative to baseline. For Weeks 3 and 4, her CO levels increased relative to
Week 2 and showed an upward trend. When the contingencies were removed at Week 5,
her CO increased to a level similar to baseline, but decreased at Session 10 to levels
provided during CM Weeks 2 – 4. At Week 6, when the contingencies were reinstated,
her CO levels decreased from the previous session and finally increased slightly. CO
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levels for Week 6 were substantially lower than both baseline weeks and similar to CM
Weeks 2 – 4.
Figure 10 shows the urinalysis scores across all condition weeks. Her urinalysis
score decreased significantly at Session 2, following intake. During CM Weeks 2 – 4, her
urinalysis scores were slightly lower than that of intake, but consistent with Session 2.
When the contingencies were removed at Week 5, urinalysis scores did not change
notably. At Week 6, when the contingencies were replaced, her urinalysis score remained
at levels similar to all previous sessions, except intake.
Self-report measures. Figure 11 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. Her daily
number or cigarettes smoked decreased substantially during baseline at Session 2 relative
to intake. Upon implementation of CM, her daily number of cigarettes increased slightly
but remained at a level lower than that of intake. At the following session, (Session 4) her
daily number of cigarettes decreased to levels below both baseline sessions. During
Weeks 3 and 4, her daily number of cigarettes smoked increased slightly but stayed at
levels equal or lower than baseline. When the contingencies were withdrawn at Week 5,
her daily number of cigarettes did not change. At Week 6, when the contingencies were
reinstated, her daily number of cigarettes decreased to levels lower than all previous
sessions.
Figure 12 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. During baseline, her time since last smoking at intake and
baseline was low and consistent for both sessions. When CM was introduced, her time
since last smoking increased substantially and remained stable for Sessions 3 – 5. During
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Sessions 5 – 7, her time since last smoking showed a declining trend, and at Session 8 her
time since last smoking increased but did not reach the higher levels reported during
Sessions 3 – 5. When the contingencies were removed, her time since last smoking
decreased but remained at levels similar to those of CM Weeks 2 – 4. Her time since last
smoking during Week 5 was significantly greater than that reported during the first
baseline condition. At Week 6, when the contingencies were reimplemented, her time
since last smoking increased initially to levels greater than all previous sessions but
decreased at her last session to a level lower than Week 5.
Attendance and earnings. Participant 11 attended all 12 sessions of the study. Of
the 8 sessions for which she could earn monetary compensation contingent on smoking,
she met all reduction criteria three times (37.5%) and did not meet all abstention criteria
for any session (0%). In total, she earned $16/2 raffle tickets for decreasing her smoking
and $72 for attending sessions and completing all required measures.
Participant 12
Biological measures. Figure 13 shows the expired breath CO levels across all
condition weeks. During baseline, her CO level decreased significantly at Session 2
relative to intake. During CM Weeks 2 – 4, her CO levels were considerably lower than
intake, but similar to Session 2’s level, with the exception of Session 8, during which her
CO level increased. At Week 5, when the contingencies were withdrawn, her CO level
decreased substantially from the previous session, but throughout the return to baseline
her CO levels were at levels comparable to CM Weeks 2 – 4. Upon reinstatement of the
CM condition, her CO levels did not change notably.
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Figure 14 shows the urinalysis scores across all condition weeks. During baseline,
her urinalysis score decreased significantly at Session 2 relative to intake. During CM
Weeks 2 – 4, her urinalysis scores fluctuated little at levels lower than intake but slightly
greater than Session 2. When the contingencies were subsequently removed, her
urinalysis score decreased minimally to a level similar to Sessions 3 and 6. There was no
change in urinalysis score relative to Week 5 when CM was reimplemented at Week 6.
Self-report measures. Figure 15 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. During baseline,
her daily number of cigarettes smoked decreased substantially from intake to Session 2.
Upon introduction of the CM intervention, her daily number of cigarettes smoked did not
change from the previous session. At Session 5, her daily number of cigarettes smoked
decreased below that reported at Session 2, and at Session 8 increased above. When the
contingencies were withdrawn at Week 5, there was no change in her daily number of
cigarettes smoked at either session. Initially, at Session 11 when CM was reintroduced
there was no change in daily number of cigarettes smoked, but at her final session there
was a decrease in level within the range of CM Weeks 2 – 4.
Figure 16 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. During the baseline week, her time since last smoking
increased considerably from intake to Session 2. When the contingencies were introduced
at Session 3, her time since last smoking increased above both baseline levels. During
Session 4 – 6, her time since last smoking decreased relative to Session 3 but was similar
or slightly greater than that reported at Session 2. At Sessions 7 and 8, her time since last
smoking rose sharply above all previous levels and declined to a level comparable to
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Session 2. Upon withdrawal of CM, her time since last smoking increased to a small
degree and remained at levels reported during CM Weeks 2 – 4 and above the initial
baseline. At Week 6, when the contingencies were reinstated, her time since last smoking
increased to levels within the range of those during CM Weeks 2 – 4.
Attendance and earnings. Participant 12 attended all 12 sessions of the study. Of
the 8 sessions for which she could earn monetary compensation contingent on smoking,
she met all reduction criteria once (12.5%) and did not meet all abstention criteria for any
session (0%). In total, she earned $8/1 raffle tickets for decreasing her smoking and $72
for attending sessions and completing all required measures.
Participant 13
Biological measures. Figure 17 shows expired breath CO levels across all
condition weeks. During baseline, her CO level decreased substantially from intake to
Session 2 (nearly 50%). Following the start of CM, her CO level increased slightly
relative to Session 2 but still was considerably lower than that of intake. During Sessions
3 – 5, her CO levels decreased continually, reaching a level lower than that of Session 2.
At Session 6, her CO level rose sharply to levels above those seen in previous CM weeks
but subsequently decreased to levels lower than Week 2 for Session 7 and 8. When the
contingencies were removed at Week 5, her CO level increased minimally. Her CO levels
during Week 5 were similar to those provided at Session 2 and significantly lower than
that of intake. During Week 6, when CM was reintroduced, her CO level decreased
slightly from the previous session and at Session 12 increased to levels consistent with
Week 5. Her CO levels during Week 6 were similar to those during CM Weeks 2 – 4.
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Figure 18 shows the urinalysis scores across all condition weeks. During Week 1,
her urinalysis scores increased from intake to Session 2. When CM was implemented, her
urinalysis score decreased to a level below both baseline sessions. At Session 5, her
urinalysis score increased above baseline levels and at Session 7 decreased to a level
similar to Session 3. When the contingencies were removed at Week 5, her urinalysis
score rose sharply to its highest level of the study and decreased to a level similar to
Week 4 at the following session. During Week 6, when CM was reintroduced, her
urinalysis score did not change and was at a level similar to those provided in CM Weeks
2 – 4.
Self-report measures. Figure 19 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. During baseline,
her daily number of cigarettes smoked decreased significantly from intake to Session 2.
When the CM intervention began, her daily number of cigarettes smoked increased
slightly relative to the previous session but was considerably lower than intake. At
Session 5, her daily number of cigarettes smoked increased above those reported at Week
2 and gradually declined through Session 7. At Session 8, her number of cigarettes
smoked increased to a near-intake level and represented the highest self-report during
CM Weeks 2 – 4. At Week 5, when the contingencies were withdrawn, her daily number
of cigarettes did not change. When CM was next reinstated at Week 6, her daily number
of cigarettes decreased relative to previous baseline to levels consistent with CM Weeks
2 – 4.
Figure 20 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. During baseline, her time since last smoking did not change
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notably. During CM Weeks 2 – 4, her time since last smoking was highly variable. At
Session 3, when CM was first implemented, her time since last smoking increased
substantially relative to baseline; however, at Session 4, her level dropped to nearly 0.
During Sessions 5 – 8, her time since last smoking showed an increasing trend, reaching
levels above those reported at baseline for Sessions 6 – 8. When the contingencies were
subsequently removed, her time since last smoking decreased considerably. Following
reimplementation of the CM intervention, her time since last smoking increased relative
to the previous baseline at levels similar to those during CM Weeks 2 – 4 and above
initial baseline levels.
Attendance and earnings. Participant 13 attended all 12 sessions of the study. Of
the 8 sessions for which she could earn monetary compensation contingent on smoking,
she never met all reduction criteria (0.0%) or all abstention criteria (0.0%). In total, she
earned $0 and 0 raffle tickets contingent on smoking and $72 for attending sessions and
completing all required measures.
Participant 15
Biological measures. Figure 21 shows the expired breath CO levels across all
condition weeks. During baseline, her CO levels decreased drastically from intake to
Session 2 (92.3%). When the CM intervention was initiated, her CO level did not change
from Session 2 but was significantly lower than that of intake. At Session 4, her CO level
increased from Session 3 but was still indicative of smoking abstinence. Sessions 6 – 8
showed a gradual reduction in CO levels, eventually reaching 0. When the contingencies
were withdrawn in Week 5, her CO levels increased slightly to levels consistent with
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those of CM Weeks 2 – 4. During Week 6, when CM was reimplemented, her CO levels
decreased to small degree from Session 10 and increased 1 ppm at her final session.
Figure 22 shows the urinalysis scores across all condition weeks. During baseline,
her urinalysis score rose slightly from intake to Session 2 and both scores were indicative
of light smoking. Upon introduction of CM at Session 3, her urine score increased
relative to Sessions 1 and 2. At Session 6, her urinalysis score decreased to 0, but at the
following session increased to a level higher than baseline scores and lower than Session
3. When the contingencies were removed, urinalysis scores decreased to 0 for both
baseline sessions and remained at this level when CM was reintroduced at Session 11.
Self-report measures. Figure 23 shows the self-reported daily number of
cigarettes smoked since the previous session across all condition weeks. During baseline,
her daily number of cigarettes smoked was relatively stable; however, within CM Weeks
2 – 4, her daily number of cigarettes smoked fluctuated considerably. When the CM
condition was implemented at Session 3, her daily number of cigarettes smoked increased
above baseline levels but quickly decreased below baseline levels at the following
session. At Sessions 6 and 7, her daily number of cigarettes smoked increased from
Session 4 and dropped significantly on Session 8. During the return to baseline week, her
daily number of cigarettes smoked increased substantially, above levels reported during
CM Weeks 2 – 4 and the initial baseline. When CM was reintroduced at Week 6, her
daily number of cigarettes decreased to levels similar to those of CM Weeks 2 – 4 and
continued decreasing to Session 12.
Figure 24 shows the self-reported time in minutes since last smoking a cigarette
across all condition weeks. During baseline, her time since last smoking increased greatly
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from intake to Session 2. When CM was implemented at Session 3, her time since last
smoking increased slightly, showing a small declining trend through Session 7. At
Session 8, her time since last smoking increased above all previous levels. When the
contingencies were removed, her time since last smoking rose at Session 9 then decreased
to levels consistent with CM Weeks 2 – 4. At Week 6, when CM was reimplemented, her
time since last smoking increased from Session 10 and continued increasing until the end
of the study.
Attendance and earnings. Participant 15 attended 11 of the 12 (87.5%) sessions.
Of the 7 sessions for which she could earn monetary compensation contingent on
smoking, she met all reduction criteria five times (71.4%) and did not meet all abstention
criteria for any session (0.0%). In total, she earned $20/4 raffle tickets for decreasing
smoking and $72 for attending sessions and completing all required measures.

CHAPTER 4
Discussion
The present study evaluated the efficacy and feasibility of a CMSC intervention
using a novel payment schedule implemented within a workplace setting to address issues
related to response requirements and behavioral costs, respectively. This study was the
first to employ a payment schedule in which abstention and reduction payments operated
concurrently. Furthermore, the current study was the first of its type to consider the
effects of a schedule in which payment magnitudes for particular smoking contingencies
decreased throughout the treatment weeks. Also, although not the first study to
implement CMSC within a workplace setting, it was the first to do so with the intention
of reducing behavioral costs for both participants and researchers. These arrangements
represent unique approaches toward an improved methodological understanding and
practical implementation of CMSC.
Although clear in its aims and objectives, the current study’s results provide
inconclusive evidence about the extent to which it did or potentially could ameliorate the
challenges associated with inadequate response requirements and high behavioral costs.
Contrary to my prediction, participants’ biological and self-reported evidence of smoking
did not systematically reduce when the novel payment schedule was present relative to
periods in which it was absent. This finding is inconsistent with the vast majority of
previously published studies on CMSC. For example, Dallery, Glenn, and Raiff (2007)
found that over 60% of participant samples met abstinence criterion during CM compared
to less than 5% during an initial baseline period. Stitzer and Bigelow (1983) obtained
similar results in a reduction-based intervention in which 42 – 72% met criterion (i.e.,
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50% reduction relative to baseline) during CM. Within a workplace setting, Rand et al.
(1989) found that participants paid contingent on smoking abstinence delayed time to
relapse significantly longer than those paid independent of smoking levels. Noteworthy
differences between these studies and the current study (e.g., CO cutoff levels, method of
data collection) do limit the extent to which their results can be compared directly;
however, despite these differences, these and other studies (see Sigmon et al., 2008) did
demonstrate that smoking levels decreased significantly as a result of CM whereas the
present study did not. Also contradictory to my hypothesis, the current design did not
retain all participants throughout the 6-week study period. This finding is contradictory to
previous CMSC studies. Although the present study required fewer visits and more
convenient locations than previous studies, the attrition rates were similar or greater than
those requiring 5 or more weekly visits (e.g., Correia & Benson, 2006) over longer
periods of time (e.g., 3 months; Lamb, et al., 2005). Furthermore, the attrition rates in the
current study were much higher than similar studies also conducted within a workplace
setting (e.g., Rand et al.; Stitzer & Bigelow). There are several limitations and concerns
that may explain partially the current study’s failure to demonstrate (a) systematic
smoking reductions during CM weeks relative to baselines and (b) high participant
retention. These limitations and concerns raise important empirical questions as to the
most optimal and practical methods of implementing CMSC.
Limitations of the Current Study and Future Directions
Failure to establish stable baseline smoking levels. Perhaps the greatest
shortcoming of the current study was the failure to establish stable baseline smoking
levels (This problem is most relevant to the initial baseline. See “Weaknesses of reversal
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designs using CM”). The establishment of a baseline in which a behavioral dimension
shows stability is essential to any single-subject analysis and serves two primary
functions (Barlow et al., 2009; Cooper et al., 2007). First, a stable baseline provides a
description of the target behavior at its natural levels (i.e., in the absence of an
independent variable); and second, a stable baseline serves as a predictor of future
behavior. For example, if a participant submits CO samples that are stable during
baseline, one can predict that subsequent levels will be similar, assuming relevant
environmental events remain unchanged. Any changes in CO levels following a
systematic manipulation (e.g., addition or withdrawal of CM) provide support that any
increase(s) or decrease(s) in level or variability are a function of the manipulation. Such
conclusions can be drawn only from reversal or multiple-baseline designs (e.g., baseline,
CM, return to baseline; see “Weaknesses of reversal designs using CM” for more on
multiple-baseline designs).
In the present study, biological and self-report data were collected just twice
during baseline. Collecting baseline data on such few occasions did not allow for a proper
assessment of trends. Furthermore, the limited number of sessions during baseline
increased the likelihood that extraneous variables (e.g., stress, access to cigarettes)
accounted for the variability relative to a design using more repeated measurements.
Most importantly, because an insufficient sample size precluded the use of statistical
methods, collecting data only twice during baseline did not allow for an experimentally
rigorous analysis of the effect CM may have had on participant’s smoking levels. In order
to address the goals of the current study more sufficiently, future researchers should
implement designs in which baseline stability is required prior to introducing CM. Doing
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so would increase the extent to which a functional relationship between CM and smoking
levels could be identified clearly.
Although experimentally ideal, to the best of my knowledge, no published CMSC
study to date has required a stable baseline period prior to introducing CM. Instead, a
consistent trend in the literature has been to specify the lengths of baseline from the
outset, typically using a timeframe of 1 – 2 weeks (e.g., Correia & Benson, 2006; Lamb
et al., 2005). There are numerous practical explanations for this approach. First, for some
participants, establishing a stable baseline may take considerably longer than 1 – 2
weeks, which would lead to more costly treatments. Second, obtaining stable smoking
levels requires frequent measurements, which would drastically increase the behavioral
costs of the participants and researchers and could increase attrition rates compared to
studies using shorter baselines. Third, daily smoking patterns are highly variable, and
stability or cyclical patterns may not emerge with many current smoking measures
(Griffith, Shiffman, & Heitjan, 2009). Given these concerns, designs requiring stable
baselines may be best suited for methodological investigations or component analyses,
whereas less stringent designs may be ample for clinical applications of CMSC.
Despite the limited amount of smoking data collected during baseline, a consistent
pattern of smoking emerged from participants’ intake sessions to their second baseline
sessions. All participants appeared to reduce their recent smoking at the second baseline
session relative to intake, as observed in all 6 participants’ CO levels and 4 participants’
urinalysis scores. This limited even further the extent to which any potential causal
relationships could be drawn. Any decreases in CO or urinalysis observed when CM was
introduced could simply represent a continuation of the decreasing levels seen during
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baseline. It is unclear what factor(s) may have influenced participant’s sharp decreases in
smoking during baseline. It is possible that participation in a smoking cessation study
increased participants’ self-monitoring of smoking, and they may have initiated smoking
reduction on their own during this time; however, previous studies suggest that selfmonitoring has little effect (Rand et al., 1989) or can actually increase smoking (McFall,
1970).
Weaknesses of reversal designs using CM. The current study used an ABAB
design consisting of baseline, CM, return to baseline, and return to CM. This design was
chosen because it offers two advantages over simpler ABA designs, which most previous
CMSC studies have used (e.g., Irons & Correia, 2008a). First, ABAB designs are
preferred from a clinical standpoint because they end on a treatment phase, which may
facilitate a participant’s transition to an alternative treatment option following the study.
Second, ABAB designs are preferred from an experimental perspective because by
including a second B phase, they are capable of demonstrating an additional change in
behavior as a function of the treatment. Although useful for the study of many clinical
problems, withdrawal designs may be inappropriate for studying CM.
Withdrawal designs operate under the assumption that a treatment can be
completely removed and reinstated. In previous studies and the present, contingencies for
smoking reduction or abstention technically were completely removed and reinstated;
however, if CM is successful, smoking levels should not return to baseline levels. The
goal of any CM treatment is to arrange artificial reinforcement contingencies to help
initiate a previously difficult or unattainable level of a target behavior. Once this level is
reached, the individual should begin to contact natural reinforcers associated with that
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target behavior level. Ideally, these natural reinforcement contingencies should be
sufficiently strong enough to maintain the desired target behavior level long-term;
therefore, when CM is removed, behavior should remain stable.
The incompatibility of a withdrawal design for CM has been documented in
several previous CMSC studies (e.g., Correia & Benson, 2006; Dallery & Glenn, 2005;
Stitzer & Bigelow, 1982). In these studies, smoking levels decreased significantly during
CM relative to an initial baseline period; however, smoking levels did not return to these
levels during a second baseline period. An experimental interpretation of these findings
suggests that variables other than CM may have been responsible for the smoking
reductions. A more plausible, clinical interpretation would suggest that CM was
responsible for the smoking reductions, and that the failure to return to baseline levels
was due to natural reinforcers that participants had begun to contact during CM, which
maintained lower smoking levels. To circumvent issues related to internal validity and to
make experimental and clinical interpretations more aligned, a nonwithdrawal design,
such as the multiple-baseline design, is necessary.
Essentially, multiple-baseline designs can be conceptualized as a series of AB
designs in which treatment is introduced in staggered intervals across individuals (Barlow
et al., 2009). Once steady-state responding is achieved during baseline, treatment is
introduced for one participant until steady-state responding is achieved during treatment.
Treatment is introduced in this fashion across all participants and is never withdrawn
during the study. The extent to which behavior changes when and only when treatment is
introduced is used as an indicator of experimental control. Multiple baselines have been
used very little in CMSC studies (e.g., Dallery & Glenn, 2005), but they may offer a
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viable approach, addressing issues related to CM’s carryover effects while maintaining
ethical standards by ending with treatment. Future research is necessary to determine the
utility of multiple-baseline designs for use with CMSC.
Practical drawbacks of smoking measurement. Objective verification of the
target behavior is an essential component of CM; however, smoking is particularly
difficult to measure. The current study used a combination of (a) expired breath CO, to
capture recent smoking (6 – 8 hours); (b) urine cotinine, to capture prolonged smoking (5
– 7 days), and (c) self-report, to capture smoking since the previous session. In using
these three measures, there was very little chance that participants could earn
compensation if they did not truly reduce or abstain from smoking. Likewise, there was
very little chance that participants were not compensated, if in fact they did reduce or
abstain. Yet, there were several factors that may have influenced participant’s smoking
measures that deserve consideration. First, all surprise sessions were intended to be
chosen randomly by day and time, but due to practical issues (e.g., some participants
could not meet certain days), certain participants had a limited number of days and times
during which surprise sessions could occur. Although unlikely, it is possible that
participants shifted their smoking patterns to attempt to meet reduction criteria for
surprise sessions. Researchers for future studies may wish to enroll only participants with
certain days and times of availability to reduce any effect this may have had.
Second, meeting times for constant sessions occurred on different days and at
different times across participants. For example, participants met with researchers on
Tuesday, Wednesday, or Thursday, with some meeting in the late morning and other
meeting in the early evening. Any day- or time-related environmental events relevant to
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smoking could have influenced smoking levels throughout the study. For example,
participants meeting earlier in the week may have provided different urine cotinine scores
compared to those meeting later in the week due to increased smoking that may have
occurred over the weekend when smoking was not monitored. From the current study,
these conclusions are difficult to reach, but future studies should consider these factors,
possibly by scheduling participants at the same time and day.
Third, implementing CMSC within the workplace has numerous advantages, but
with more employers banning smoking among employees (Fichtenberg & Glanz, 2002),
the use of CO and other measures of recent smoking may not provide a valid index
suitable for CM interventions. The workplaces included in the present study allowed
smoking outdoors but prohibited smoking within public buildings. I did not assess
smoking levels during working versus nonworking hours, and it is possible that
differences existed that affected treatment outcomes. Other researchers implementing CM
within the workplace should consider these factors and may need to adjust their methods
of verifying smoking accordingly.
Fourth, the time intervals between sessions were not held constant during weeks
in which CM was in place. Time intervals between sessions varied from 0 – 2 days
during weekdays and up to 6 days including the weekend, which may have created
situations in which participants reduced or abstained from smoking, but did not earn
compensation (e.g., a participant with sessions on a Monday and Thursday may have
reduced or abstained on Wednesday). Future studies may need to require more frequent
measurements to determine the extent to which this occurs. Also, future researchers may
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want to explore the effects of different time intervals between sessions on treatment
outcomes.
Payment magnitudes and cost-effectiveness. In the current study, participants
could earn an average of $6 contingent on smoking reduction and an average of $19.63
contingent on smoking abstention at each session. Compared to most previous CMSC
studies, payment magnitudes for the present study were considerably higher, which
presumably should have led to lower smoking levels and higher abstention rates than
lower payment magnitudes (Correia & Benson, 2006; Stitzer & Bigelow, 1983). One
explanation for the current study’s failure to show reduced smoking levels may be that
payment magnitudes were insufficient. Low payment magnitudes may have contributed
also to participant attrition, although these payments were exceptionally high (i.e.,
average of $15 per session during baselines and $1.50 during CM weeks) compared to
other CMSC studies. The selection of the average monetary payments per session was
informed from a previous study (Irons & Correia, 2008b), in which college student
smokers indicated monetary amounts for which they would completely abstain from
smoking for various periods of time (e.g., 1 day, 1 week). The current study used a
sample of middle-aged adults holding full-time jobs who likely had higher personal
incomes than participants in Irons’ study. It is possible that individuals with greater
personal incomes require higher payment magnitudes to initiate smoking reduction or
abstinence. Some researchers (e.g., Dallery & Glenn, 2005) have begun to publish
demographic information related to personal income, but no empirical methods exist on
how to use this information. Determining whether and the extent to which personal
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income affects smoking outcomes is a necessary step toward creating more efficient
CMSC interventions.
Other differences in sample characteristics between Irons and Correia (2008b) and
the present study, such as the number of years smoked (i.e., older smokers are more
likely to have smoked longer), also could moderate the relationship between payment
magnitude and smoking outcomes. Moreover, the reduction payments were established
based on data for smoking abstinence. At present, there are no studies that have
investigated the relationship between payments for smoking reduction and abstention. In
the current study, reduction payments were significantly lower than those for abstention.
However, it is still unclear whether payment magnitudes for reduction and abstention
would be most beneficially arranged in a linear (e.g., 50% [25%] reduction criterion
would result in 50% [50%] of the abstinence payment magnitude) or nonlinear fashion
(e.g., payment magnitudes for reduction would change relative to abstinence magnitudes
over the course of treatment). Further understanding of the relationship between response
requirements and payment magnitudes is essential for creating CMSC interventions that
are cost-effective, an aim that is arguably the greatest barrier to its wide-spread adoption.
Recently, more strategies to decrease CM costs have been explored. Petry and
colleagues (2002, 2000) employed variable value (i.e., lottery-based) contingencies using
CM for the treatment of substances other than nicotine and obtained results consistent
with those employing standard monetary payments, while keeping treatment costs low. A
similar approach was used in the present study, in which participants could earn one
raffle ticket contingent on smoking reduction and two raffle tickets contingent on
smoking abstention at each session, which were entered into a lottery for a $75 VISA®
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check card. Other methods for increasing the cost-effectiveness of CMSC include (a)
funding treatments through community donations (e.g., Donatelle, Prows, Champeau, &
Hudson, 2000), (b) deposit contracting (e.g., Dallery, Meredith, & Glenn, 2008) , and (c)
treatment fee rebates (see Amass and Kamien, 2008, who discuss this approach and the
others at length). Future researchers also may want to search for reinforcers that have
additional health benefits or address other societal problems related to smoking,
especially among at-risk populations and/or those in underserved areas. For example,
individuals with little formal education or deficient English skills who successfully
reduce or abstain from smoking could enroll in classes taught by volunteers or receive
donated educational technology software/hardware. These individuals could experience a
number of benefits above and beyond smoking cessation (e.g., education could lead to a
better-paying job, language skills could allow parents to finally help their children with
schoolwork). Indeed, CM arrangements that address societal problems that co-occur with
substance abuse have been extremely successful (e.g., unemployment and heroin/cocaine
use; Silverman, Svikis, Robles, Stitzer, & Bigelow, 2002) and have the potential to be
highly cost-effective.
Delayed payments. One potential strength of implementing CMSC within the
workplace is that payments can be incorporated easily into the existing payroll system,
reducing many administrative burdens that might deter employers from enrolling.
However, typical payroll systems in the United States distribute paychecks at varying
delays, with most ranging from weekly to monthly. In the current study, participants were
told that payments would be added to their bi-monthly paychecks, and that they could
expect their first payment within 1 to 3 weeks from their first session. During Week 3,

69
several participants reported that they had not received their study payments. Due to a
payroll processing error, study payments were not distributed as planned, and participants
received their payments as one lump sum roughly 7 to 8 weeks following their intake
session. A failure to provide more immediate payments contingent on smoking and
attendance may explain the current study’s inability to reduce smoking levels and to
retain participants.
A large body of basic nonhuman animal and human research has shown
unequivocally that reinforcers delivered immediately following a target behavior increase
that behavior substantially more than reinforcers delivered following some delay (Chung
& Herrnstein, 1967; Cooper et al., 2007; Madden, 2000; Vuchinich & Heather, 2003).
Said differently, individuals value immediately available reinforcers more so than those
that are available at a delay (e.g., $1 available now is more valuable than $1 tomorrow).
This phenomenon, generally referred to as temporal or delay discounting, is especially
pertinent to the study of substance abusers, including smokers, who tend to discount
delayed reinforcers significantly higher than non- or ex-smokers (Bickel, Odum, &
Madden, 1999). Roll, Reilly, and Johanson (2000) examined the effects of delayed
payment in a laboratory model of CM, during which participants could choose to take
puffs from a cigarette or receive money delivered immediately or at a delay. They
showed that when the cigarette and monetary consequences were available immediately,
participants abstained from smoking significantly more than when both were delivered at
a delay. This finding suggests that when possible, researchers and clinicians should
provide payments immediately following verification of smoking reduction or abstention
to maximize CM’s efficacy. Lussier et al. (2006) corroborated Roll et al.’s results and
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showed that the effect size for CM studies providing immediate reinforcer delivery was
roughly twice that of those providing delayed reinforcement.
Given these findings, the results of the current study are not surprising. Payments
delayed 7 to 8 weeks following attendance and verification of a behavior are not likely to
have a significant impact. The long delay for payments was unplanned, but nevertheless
it does raise important questions about the feasibility of CMSC within the workplace. The
current study processed just nine individuals’ payments. Larger studies within a
workplace might demand updated payroll systems or additional staff, which some
employers may not be able to afford. Another potential challenge for future studies
relates to the delay to payment itself. The current study was unable to determine if
payments delivered bi-monthly could initiate and maintain smoking reduction and
abstinence. Future researchers should examine differing delays within the workplace to
consider the clinical and practical advantages and disadvantages of each.
Payment arrangements. Many of the issues described above limit the extent to
which any conclusions can be drawn regarding the novel payment arrangements used in
the present study, but several aspects of the arrangements deserve consideration. The
payment arrangements of the present study provided abstention and reduction payments
concurrently in an attempt to accommodate smokers who were not able to abstain
immediately and those who were. Abstention payments escalated in magnitude across
treatment weeks, whereas reduction payments decreased in magnitude. This arrangement
increased the reinforcing value of abstention relative to reduction over time, with the
intention of facilitating a transition to complete abstention later in the study for those
gradually reducing in the early treatment weeks.
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A major limitation of these payment arrangements was that magnitudes changed
across weeks, regardless of whether participants were able to initiate smoking reduction.
For example, during the first week of CM, 2 of the 6 participants were unable to meet
reduction criteria for both sessions. During the following week (Week 3), payment
magnitudes for reduction decreased by 50% for all participants. Although the abstention
payment increased 33% during this week, the participants who were unable to initiate
reduction the week prior would be less likely to do so during Week 3, based on previous
studies on payment magnitudes (e.g., Stitzer & Bigelow, 1983). Furthermore, these
participants would not be expected to completely abstain during Week 3. An additional
weakness of these arrangements was that despite obtaining initial reductions, no
participants transitioned to smoking abstinence. This suggests that (a) absolute abstinence
payment magnitudes were insufficient or too delayed or (b) the relative difference
between abstention and reductions payments was too small. There are several options that
future studies might investigate to improve upon the present study’s payment
arrangements. Payment magnitudes for smoking reduction could decrease on an
individual rather than weekly basis. This would increase the likelihood that participants
earn smoking-contingent reinforcement, but this method would provide no guarantee. A
potential solution would be to use an arrangement in which reduction payments escalate
in magnitude based on individual smoking levels. In this way, participants who fail to
contact reduction contingencies early in treatment could have another opportunity to
reduce at a higher magnitude, which should increase the likelihood of earning payment.
For example, if a participant failed to reduce during the first week of treatment for a
payment magnitude of $10, his or her next payment would increase in magnitude the
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following week. Another approach to ensure contact with reinforcement could be to
lower reduction criteria on an individual basis. For example, if a participant failed to
reduce during the first week of treatment when reduction criterion was a 30% reduction,
the following week could become less stringent (e.g., 20%). Both components (i.e.,
magnitude and criteria) also could be modified simultaneously; however, reducing
criteria may be limited by the types of measures used to verify smoking. A traditional
escalating magnitude payment arrangement, in which successive reductions or
abstentions result in subsequent magnitude increases, also could be incorporated (Roll et
al., 1996). Escalating magnitude payment arrangements are now a standard practice in
CMSC and may lead to better treatment outcomes. Finally, the present schedule might be
improved by adding a reset contingency (e.g., Roll & Higgins, 2000), which has been
shown to increase sustained smoking abstinence.
Conclusion
The results of the present study pose more questions than they provide answers.
The methodological and practical limitations discussed above highlight an ongoing
struggle within the CM literature. There is no question that CM can initiate and maintain
smoking reduction and abstinence; however the extent to which these findings, many of
which were discovered in highly controlled settings, can generalize to real-world
environments and applications remains a challenge. Researchers are well-aware of this
challenge, and many have begun to develop innovative approaches to improve CM’s
effectiveness. Nevertheless, some fundamental areas of CM (e.g., payment schedules)
have received little attention in recent years, perhaps due to greater funding opportunities
for randomized controlled trials. These seldom investigated research areas may prove to
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be equally important to further development of CM interventions, and a return to the
human operant and basic nonhuman animal research laboratories where CM’s core
principles were discovered may be necessary. Given the clear clinical potential of CM,
research into its application will continue to increase, but the results of the current study
demonstrate the dearth of basic knowledge that needs addressing in order to harness this
powerful technology to its fullest potential.
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Footnote
1

Although often referred to as shaping, technically this is incorrect. Shaping involves

providing reinforcers contingent upon successive changes in response typographies that
more closely approximate some ultimate goal. In a changing criterion design, the target
response typography remains constant and reinforcers are provided contingent upon
successive changes in some quantifiable dimension of that target. Thus, changing
criterion design is a more accurate way of describing the implementation of percentile
schedules of reinforcement in CM. See Cooper et al. (2007) for more on this distinction.

75
Appendix A
Demographics Questionnaire
1) What is your participant ID?
2) Gender
Male
Female
3) What is your age?
4) Race
Asian
Black or African American
White
Hispanic or Latino
American Indian or Alaska Native
Native Hawaiian or other Pacific Islander
Multi-ethnic
Other
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Appendix B
Smoking Behavior Questionnaire
1) On how many days of the week do you smoke cigarettes?
2) How old were you when you began to smoke cigarettes regularly?
3) For how many hours, on average each day, are you closely subjected to other
people’s tobacco smoke?

NOTE: “closely subjected” means that you see, smell, or inhale tobacco smoke

4) How many times have you tried to quit smoking?
5) How interested are you in stopping smoking?
Strongly
Very
Somewhat
A little
Not at all
6) Have you ever tried to stop smoking before using the following methods?
Clinical or group
Gradual reduction
Written materials
Hypnosis
Special filters
Self-help program
Cold turkey
Stop with a friend
Medication
Other
7) Are you currently using any of the following methods to stop smoking?
Clinical or group
Gradual reduction
Written materials
Hypnosis
Special filters
Self-help program
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Cold turkey
Stop with a friend
Medication
Other
8) Do you plan to use any of the following methods to quit smoking in the next 6
weeks?
Clinical or group
Gradual reduction
Written materials
Hypnosis
Special filters
Self-help program
Cold turkey
Stop with a friend
Medication
Other
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Appendix C
Hooked on Nicotine Checklist
Indicate your answer, “yes” or “no”, for the following 10 questions:
Have you ever tried to quit using tobacco products, but couldn't?
Do you smoke now because it really hard to quit?
Have you ever felt like you were addicted to tobacco?
Do you ever have strong cravings to smoke?
Have you ever felt like you really needed a cigarette?
Is it hard to keep from smoking at times or in places where others are not?
When you haven't smoked for a while
OR
when you tried to stop smoking...

...did you find it hard to concentrate because you couldn't smoke?
...did you feel more irritable because you couldn't smoke?
...did you feel a strong need or urge to smoke?
...did you feel nervous, restless or anxious because you couldn't smoke?
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Appendix D
Fagerstrom Test for Nicotine Dependence
How soon after you wake up in the morning do you smoke your first cigarette?
After 60 minutes
31-60 minutes
6-30 minutes
Within 5 minutes
Do you find it difficult to refrain from smoking in places where it is forbidden?
Yes
No
Which cigarette would you hate most to give up?
First in the morning
Any other
How many cigarettes do you smoke per day?
10 or less
11-20
21-30
31 or more
Do you smoke more frequently during the first part of the day after awakening than
during the rest of the day?
Yes
No
Do you smoke when you are so ill that you are in bed most of the day?
Yes
No

80
Appendix E
Wisconsin Smoking Withdrawal Scale
All items are rated on a 5-point scale (0 = strongly disagree, 4 = strongly agree)
Food is not particularly appealing to me.
I am getting restful sleep.
I have been tense or anxious.
My level of concentration is excellent.
I awaken from sleep frequently during the night.
I have felt impatient.
I have felt upbeat and optimistic.
I have found myself worrying about my problems
I have had frequent urges to smoke.
I have felt calm lately.
I have been bothered by the desire to smoke a cigarette.
I have felt sad or depressed.
I have been irritable, easily angered.
I want to nibble on snacks or sweets.
I have been bothered by negative moods such as anger, frustration, and irritability.
I have been eating a lot.
I am satisfied with my sleep.
I have felt frustrated.
I have felt hopeless or discouraged.
I have thought about smoking a lot.
I have felt hungry.
I feel that I am getting enough sleep.
It is hard to pay attention to things.
I have felt happy and content.
My sleep has been troubled.
I have trouble getting cigarettes off my mind.
It has been difficult to think clearly.
I think about food a lot.
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Appendix F
Contemplation Ladder
Each rung on this ladder represents where various smokers are in their thinking about
quitting. Check the number that indicates where you are now. PLEASE CHECK ONLY
ONE.
Rung 0
No thought about quitting
Rung 1
Rung 2
Think I need to consider quitting some day
Rung 3
Rung 4
Rung 5
Think I should quit but not quite ready
Rung 6
Rung 7
Starting to think about how to change my smoking patterns
Rung 8
Rung 9
Rung 10
Taking action to quit
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Appendix G
Daily Tobacco Report
On average, how many cigarettes per day have you smoked since your last session?
Have you smoked cigarettes over the last 24 hours?
Yes
No
If YES, how many cigarettes have you smoked over the last 24 hours?
If YES, how long ago did you smoke your last cigarette? (Hrs or min)
Have you smoked any cigars over the last 24 hours?
Yes
No
If YES, how many cigars have you smoked over the last 24 hours?
IF YES, how long ago did you smoke your last cigar? (Hrs or min)
Have you smoked any pipe tobacco over the last 24 hours?
Yes
No
If YES, how many times did you smoke pipe tobacco over the last 24 hours?
IF YES, how long ago did you smoke your last pipe tobacco? (Hrs or min)
Have you had any chewing tobacco over the last 24 hours?
Yes
No
If YES, how many times did you use chewing tobacco over the last 24 hours?
IF YES, how long ago you last use chewing tobacco? (Hrs or min)

83
Appendix H

84
Appendix I
NicCheckTM I Test Strips
For Use in the Detection of Nicotine and/or its Metabolites in Urine
Background
In recent years, the knowledge and awareness of health hazards associated with
tobacco consumption (especially from smoking cigarettes) has increased. Surgeon
Generals' Reports of the U.S. Public Health Service (PHS) have identified cigarette
smoking as one of the most significant causes of death and disease in the U.S. This
awareness has also increased all over the world. Smoking is cited as one of the major
causes of cancer (1, 2); it is responsible for an estimated 30% of all cancer deaths
including 87% of lung cancer, the leading cause of cancer mortality. It is also responsible
for 21% of deaths from coronary heart disease, 18% of stroke deaths, and 82% of deaths
from chronic obstructive pulmonary disease (3). Other forms of tobacco use, including
pipe and cigar smoking and the use of smokeless tobacco, are also associated with
significantly elevated risks of disease and death (4, 5).
Self-reports of smoking behavior have been shown to be unreliable (6, 7, 8, 9).
The availability of sensitive and reproducible analytical methods has led to the increased
use of biochemical markers for the measurement of tobacco consumption (10).
Measurement of carbon monoxide, carboxyhemoglobin or thiocyanate in the blood, or of
nicotine/cotinine in plasma, saliva or urine have been used to validate self-reported
smoking habits. However, none of these methods are satisfactory for routine use.
Measurement of expired carbon monoxide or carboxyhemoglobin levels and thiocyanate
levels may vary due to exposures unrelated to smoking, such as traffic emissions and diet
(11). Nicotine is a tobacco-specific alkaloid with a half-life of 2 hours in blood. Its
principal metabolite cotinine (12), has an average half-life of 20 hours in urine (13, 14),
making it a reasonable candidate for use as a biochemical marker for tobacco
consumption.
The NicCheck I test is a simple test that detects nicotine and/or its metabolites in
urine as a means to identify habitual consumers of tobacco. It can also differentiate
nicotine consumers into “low” versus “high” categories. For the classification of smokers
by the NicCheck I test as positive or negative based on comparison to GC urine cotinine
values, individuals with cotinine values of 200 ng/mL and above were classified as
smokers and those with cotinine values of less than 200 ng/mL were considered
nonsmokers. The NicCheck I test is suited for routine use since it is technically simple to
perform, and requires no instrumentation. Test results are available within 15 minutes.
There appears to be an increasing need to not only verify an individual's smoking
status, but also to be able to know the level of nicotine consumption. The number of
cigarettes smoked is not a true reflection of the nicotine consumed since the kinds of
cigarettes smoked are different, the intensity with which cigarette smoke is inhaled can
vary considerably from individual to individual, and the metabolism of nicotine in
individuals can also vary. Thus, two individuals smoking the same number of cigarettes
may have vastly different nicotine levels in their system. Determining the level of
nicotine consumption, for example, can be important to aid individuals to quit their
smoking habit. There is increasing evidence that a person with low nicotine dependence
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may require lower nicotine replacement therapy when compared to an individual who is
more highly nicotine dependent. Additionally, monitoring the decrease in the color
intensity on the NicCheck test strip may serve as an indicator of decreasing nicotine
consumption during smoking cessation efforts and may provide the patient with positive
reinforcement. The test may also be used to verify cessation. A test such as the NicCheck
I test would provide a simple, inexpensive and rapid method for determining the smoking
status of the individual and in identifying the smoker as a low or high nicotine consumer.
Test Description
The NicCheck test strip has four chemicals spotted along the length of the strip at
definite intervals. In testing for the presence of nicotine and its metabolites in urine, the
NicCheck I test strip is placed (diethylthiobarbituric acid end first) into approximately 0.5
mL of urine contained in a suitable test tube. When urine diffuses up the test strip, the
potassium thiocyanate mixes with chloramine-T on the strip, releasing cyanogen chloride.
The cyanogen chloride then reacts with the nicotine (and/or its metabolites), if present, in
the urine. Diethylthiobarbituric acid reacts with the resulting glutaconaldehyde to
produce a pale pink to dark pink color along the length of the test strip and in the liquid
remaining at the bottom of the tube.
Handling Procedures
Each test strip should be carefully removed from the canister by only handling the
strip at the arrow end. Handling other parts of the test strip must be avoided.
Alternatively, a pair of clean forceps may be used to remove the strips from the canister.
The test strip must be placed in the urine sample (approximately 0.5 mL) with the
indicator arrow pointing downward in order for the urine sample to diffuse past the
reagents in the proper sequence. The test sample container (a 13 x 100 mm glass tube is
recommended) must be long enough to enclose the length of the entire test strip. The
canister must be closed tightly after removal of the required number of strips.
Storage Instructions
NicCheck I test strips do not require refrigerated shipping. Upon receipt, the
canister should be kept at 2-8 oC. The test strips should be protected from unnecessary
light and humidity to prevent light-induced and moisture-induced deterioration of the
reagents on the test strip.
In general, when stored in the tightly closed canister at 2-8 oC, the test strips can
be used for at least two years from the date of manufacture. Since the test strips are
susceptible to conditions of high humidity, the canister must be kept tightly closed after
removal of the required number of strips.
Indications of Instability
While a pale brown color may be observed at the lower end of an unused test
strip, this does not indicate a degradation of the test strip and does not interfere with the
reaction. However, a bright yellow or dark brown color observed elsewhere on the test
strip may indicate instability. Quality control checks using NicCheck I Human Urine
Positive and Negative Test Controls (sold separately) should be performed whenever
instability is suspected.
Specimen Collection and Preparation
NicCheck I test strips may be used with any freshly voided, stored (refrigerated or
frozen) urine specimens or with urine collected under special conditions, such as first-
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morning specimens and post-prandial urine specimens. The urine specimen must be
collected in a clean container. Preservatives must not be added to the urine specimen. If
testing cannot be performed within 4 hours after collection of the urine, the specimen
must be stored at 2-8 oC. If stored at 2-8 oC, testing must be performed within 48 hours.
The specimens must be brought to room temperature prior to testing, and mixed
thoroughly before use. The test may also be performed on specimens stored frozen at -20
o
C. The frozen specimens may not be frozen and thawed more than three times. Studies
beyond three freeze-thaw cycles have not been conducted. If stored frozen, the specimens
must be thawed and brought to room temperature prior to testing.
It should be noted that the NicCheck I test strips function appropriately in the pH
range of 4.5-8.5. The NicCheck I test may react as false negative if the pH of the urine is
outside of this range. Normal urine has a pH of 4.5-8.0 with an average pH of 6.0.
Test Description
1.
Obtain a urine specimen and transfer 0.5-1.0 mL of urine to a 13 x 100 mm test
tube or equivalent.
2.
Remove a NicCheck I test strip from the canister, handling the strips only at the
arrow end. Do not touch any other part of the test strip. Alternatively, a clean pair of
forceps may be used to remove the test strip from the canister.
3.
Place the test strip directly into the urine specimen with the arrow pointing
downward into the specimen.
4.
After introduction of the test strip into the specimen, observe results at 15
minutes. For differentiation into “low” versus “high” consumption of nicotine,
comparison of the test results to the color chart provided must also be performed at 15
minutes.
Materials Provided
Fifty (50) NicCheck I test strips are provided with each kit. A color chart for the
differentiation of smokers into “low” versus “high” consumers of nicotine is also
provided with each kit.
Materials Required But Not Provided
13 x 100 mm test tubes (or equivalent), Forceps (optional), and a test tube rack
Interpretation of Results
The appearance of a pale pink to dark pink color on the strips is a positive
reaction and indicates the presence of nicotine and/or its metabolites in the specimen.
Occasionally, colors in the spectrum of orange to reddish pink may be observed. These
are also to be considered as true positive reactions. Color development must occur along
the length of the test strip. The intensity of color on the strip at the end of 15 minutes may
be compared to those on the color chart, to differentiate between “low” versus “high”
nicotine consumption.
If the color along the length of the test strip is less in intensity than the pink color
on the color chart, the result is read as a “low” positive. If the color on the test strip
matches in intensity or is darker in intensity than the pink color on the color chart, the
result is interpreted as a “high” positive. Absence of a color in the pink to red spectrum is
considered a negative result.
Note: As the NicCheck I test reaction occurs (positive or negative), it is normal for a
bright yellow color to develop at the top end of the strip (near the arrows).
Limitations of the Procedure
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If reactions with positive and negative test controls are not as expected, unused
test strips should not be used, and the distributor and/or manufacturer should be notified.
Consumption of therapeutic levels (daily dose of 500 mg or greater) of niacin may result
in a false-positive reaction by the NicCheck I test.
Reliable results and proper interpretation of results are dependent on performing
the procedure as described in the package insert.
For the correct result to be obtained with the NicCheck I test, it is important to note the
following conditions under which proper color development on the test strip may be
impeded.
Delivering more than 1 mL of urine into the test tube for the NicCheck I test may
result in improper color development due to inability of the sequential reaction to occur.
Delivering less than 0.5 mL of urine will be insufficient to wet the full length of the test
strip.
Using a beaker or urine collection container for performing the NicCheck® I test
is unacceptable. Since the color development depends upon the sequential reaction of
reagents along the entire length of the test strip, it is important to use a narrow test tube
which is long enough to enclose the entire length of the strip.
For color development, the test strip must be placed with the arrow pointing
downward into the tube.
Urine must be delivered directly to the bottom of the test tube in order to avoid
sticking of the test strip to the inner wall of the tube. If the test strip sticks to the inner
wall of the test tube, it does not allow for proper color development along the length of
the test strip. The test must be repeated if this occurs.
Under conditions of high humidity, the test tube containing the NicCheck I test
strip must be kept covered.
The NicCheck I result must be read 15 minutes after introduction of the test strip
into the urine. Reading the reaction after 25 minutes may result in a decrease in the color
intensity on the NicCheck test strip.
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Appendix J
Debriefing Statement
The purpose of this study was to examine an intervention designed to help individuals
reduce their smoking. If participation in this study caused you any discomfort or distress,
you should visit one of the following:
o Counseling and Student Development Center located in Varner House, immediately
adjacent to the statue of James Madison and the Hoffman Hall bus stop in the
Bluestone area of campus (540.568.6552; http://www.jmu.edu/counselingctr/)
o University Health Center located next to Burruss Hall, at the corner of Mason and
Grace St, adjacent to Rockingham Memorial Hospital, (540.568.6178;
http://www.jmu.edu/healthctr/)
For more information on how you can quit smoking, visit the US Department of Health
and Human Services Centers for Disease Control and Prevention Smoking and Tobacco
Use web page at http://www.cdc.gov/tobacco/quit_smoking/index.htm or one of these
other reputable web sites that address smoking cessation.
http://www.smokefree.gov/
http://www.nlm.nih.gov/medlineplus/smokingcessation.html
http://www.cancer.gov/cancertopics/factsheet/Tobacco/cessation
http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=22931
http://www.surgeongeneral.gov/tobacco/
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Figure 1. Expired breath CO across all condition weeks for Participant 3. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels.
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Figure 2. Urinalysis scores across all condition weeks for Participant 3. Short, solid dash
marks represent reduction/abstention criterion.
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Figure 3. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 3. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 3’s response to the question, “On average, how many cigarettes do
you smoke each day?”.
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Figure 4. Self-reported time in minutes since last smoking a cigarette across all condition
weeks for Participant 3. Longer, dotted lines represent weekly mean levels. Payment was
not contingent on time since last smoking, therefore no reduction/abstention criteria are
shown.
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Figure 5. Expired breath CO across all condition weeks for Participant 8. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels.
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Figure 6. Urinalysis scores across all condition weeks for Participant 8. Short, solid dash
marks represent reduction/abstention criterion.
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Figure 7. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 8. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 8’s response to the question, “On average, how many cigarettes do
you smoke each day?”
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Figure 8. Self-reported time in minutes since last smoking a cigarette across all condition
weeks for Participant 8. Longer, dotted lines represent weekly mean levels. Payment was
not contingent on time since last smoking, therefore no reduction/abstention criteria are
shown.
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Figure 9. Expired breath CO across all condition weeks for Participant 11. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels.

116

Participant 11
14
Urinalysis Score

12
10
8
6
4
2
0
0

1

2

3

4

5

6

7

8

9

10

11

12

Sessions

Figure 10. Urinalysis scores across all condition weeks for Participant 11. Short, solid
dash marks represent reduction/abstention criterion.
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Figure 11. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 11. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 11’s response to the question, “On average, how many cigarettes
do you smoke each day?”
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Figure 12. Self-reported time in minutes since last smoking a cigarette across all
condition weeks for Participant 11. Longer, dotted lines represent weekly mean levels.
Payment was not contingent on time since last smoking, therefore no reduction/abstention
criteria are shown.
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Figure 13. Expired breath CO across all condition weeks for Participant 12. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels.
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Figure 14. Urinalysis scores across all condition weeks for Participant 12. Short, solid
dash marks represent reduction/abstention criterion.
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Figure 15. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 12. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 12’s response to the question, “On average, how many cigarettes
do you smoke each day?”
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Figure 16. Self-reported time in minutes since last smoking a cigarette across all
condition weeks for Participant 12. Longer, dotted lines represent weekly mean levels.
Payment was not contingent on time since last smoking, therefore no reduction/abstention
criteria are shown.
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Figure 17. Expired breath CO across all condition weeks for Participant 13. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels.
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Figure 18. Urinalysis scores across all condition weeks for Participant 13. Short, solid
dash marks represent reduction/abstention criterion.
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Figure 19. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 13. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 13’s response to the question, “On average, how many cigarettes
do you smoke each day?”
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Figure 20. Self-reported time in minutes since last smoking a cigarette across all
condition weeks for Participant 13. Longer, dotted lines represent weekly mean levels.
Payment was not contingent on time since last smoking, therefore no reduction/abstention
criteria are shown.
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Figure 21. Expired breath CO across all condition weeks for Participant 15. Short, solid
dash marks represent reduction criterion. Longer, dotted lines represent weekly mean
levels. The datum for Session 5 is not shown because Participant 15 missed that session.
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Figure 22. Urinalysis scores across all condition weeks for Participant 15. Short, solid
dash marks represent reduction/abstention criterion. The datum for Session 5 is not
shown because Participant 15 missed that session.
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Figure 23. Self-reported daily number of cigarettes smoked since the previous session
across all condition weeks for Participant 15. Short, solid dash marks represent reduction
criterion. Longer, dotted lines represent weekly mean levels. The value for Session 1
represents Participant 15’s response to the question, “On average, how many cigarettes
do you smoke each day?” The datum for Session 5 is not shown because Participant 15
missed that session.
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Figure 24. Self-reported time in minutes since last smoking a cigarette across all
condition weeks for Participant 15. Longer, dotted lines represent weekly mean levels.
Payment was not contingent on time since last smoking, therefore no reduction/abstention
criteria are shown. The datum for Session 5 is not shown because Participant 15 missed
that session.

